**CURRICULUM VITAE**

**DATE:** September 21st, 2021

**NAME:**  Andrew M. Evens (Andy)

**TITLES:** Professor of Medicine, Rutgers Robert Wood Johnson Medical School

Associate Vice Chancellor, Clinical Innovation and Data Analytics, Rutgers Biomedical and Health Sciences, Rutgers University

Associate Director, Clinical Services, Rutgers Cancer Institute of New Jersey

Medical Director, Oncology Service Line, and Oncology Lead for the Combined Medical Group, RWJBarnabas Health

**HOME ADDRESS:** 21 Raspberry Trl, Warren, NJ 07059

**OFFICE ADDRESS:** Division of Blood Disorders, 195 Little Albany St, New Brunswick, NJ 08901

**TELEPHONE/E-MAIL:** 1-732-235-2465 (work) 1-312-479-2591 (cell)

 andrew.evens@rutgers.edu (work) and dramevens@mac.com (personal)

**BIRTHPLACE:** Buffalo, New York

**CITIZENSHIP:** USA

**EDUCATION:**

A. Undergraduate Graduate

 Saint Joseph’s College

 Rensselaer, IN

 B.S. Biochemistry June 1991

B. Graduate and Professional

1982 Chicago College of Osteopathic Medicine

 Downers Grove, IL

 Doctor of Osteopathy (DO) June 1996

,

Northwestern University

 Chicago, IL

 M.Sc. Clinical Investigation December 2003

 Rutgers School of Business

 Newark, NJ

 Executive MBA  *May 2022 (pending)*

 *Program description:* <https://www.business.rutgers.edu/executive-mba/program-overview>

**POSTGRADUATE/POSTDOCTORAL TRAINING:**

A. Internship and Residencies

Lutheran General Hospital, Park Ridge, IL

Internship and Residency in Internal Medicine

July 1996 – June 1999

B. Research Fellowships

Lutheran General Hospital, Park Ridge, IL

Chief Medical Resident, Medicine

July 1999 – June 2000

C. Postdoctoral Appointments

Northwestern University, Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Fellowship, Hematology/Oncology (Chief Fellow)

July 2000 – June 2003

**MILITARY:** n/a

**ACADEMIC APPOINTMENTS:**

 Department of Medicine

 Northwestern University Feinberg School of Medicine

 Instructor in Medicine

 July 2003 – August 2006

 Department of Medicine

 Northwestern University Feinberg School of Medicine

 Assistant Professor of Medicine

 September 2006 – October 2009

 Department of Medicine

 Northwestern University Feinberg School of Medicine

 Associate Professor of Medicine

 November 2009 – January 2011

 Department of Medicine

 The University of Massachusetts Medical School

 Associate Professor of Medicine

 January 2011– July 2013

 Graduate School of Biomedical Sciences (GSBS), Cell Biology

 The University of Massachusetts Medical School

 Full Faculty Member

 May 2013 – present

 Tufts Medical Center and Tufts University School of Medicine

 Professor of Medicine

 July 2013 – December 2018

Rutgers Robert Wood Johnson Medical School

Professor of Medicine

January 2018 - current

**HOSPITAL APPOINTMENTS**

Lutheran General Hospital, Park Ridge, IL

Attending Physician

(Chief Resident)

July 1999 – June 2000

Northwestern Memorial Hospital, Chicago, IL

Attending Physician

July 2003 – January 2011

UMass Memorial Medical Center, Worcester, MA

Attending Physician

January 2011 – July 2013

Tufts Medical Center, Boston, MA

 Attending Physician

July 2013 – December 2017

Robert Wood Johnson University Hospital and Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Attending Physician

January 2018 – current

**OTHER EMPLOYTMENT OR MAJOR VISITING APPOINTMENTS: n/a**

**ACADEMIC APPOINTMENTS**

**ADMINISTRATIVE APPOINTMENTS:**

Hematology-Medical Oncology Fellowship Training Program Department of Medicine

Northwestern University

Associate Director

July 2003 – June 2006

Robert H. Lurie Comprehensive Cancer Center

Northwestern University

Full Member

June 2005 – January 2011

 Translational Therapeutics, Division of Hematology/Oncology

The Robert H. Lurie Comprehensive Cancer Center of Northwestern University

 Director

 June 2009 – January 2011

 Lymphoma Disease-Oriented Section of The University of Chicago N01 Phase II Clinical Trial Consortium

Team Leader

 January 2010 – January 2011

Deputy Director, Clinical and Translational Research for the UMass Medicine Cancer Center and The University of Massachusetts Medical School

 Deputy Director

January 2011- July 2013

 Director, Lymphoma Program, Division of Hematology/Oncology, The University of Massachusetts and the UMass Medicine Cancer Center

 Director

 January 2011- July 2013

 Medical Director, UMass Medicine Cancer Center of Excellence, Clinical Research Office (CRO)

 Medical Director

January 2011- July 2013

 ECOG Institutional Principal Investigator, The University of Massachusetts and the UMass Medicine Cancer Center

 ECOG Institutional Principal Investigator

 December 2011 – July 2013

 Consultant, Clinical Trials Management Systems (CTMS) and Population Sciences Groups, National Cancer Informatics Program (NCIP), Center for Biomedical Informatics and Information Technology (CBIIT), NCI

 Consultant

 December 2012 – December 2016

 Director, Lymphoma Program, Tufts Cancer Center, Boston, MA

 Director

 July 2013 – December 2017

Chief, Division of Hematology/Oncology Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, Boston, MA

 July 2013 - December 2017

Tufts Cancer Center, Boston, MA

 ECOG Institutional Principal Investigator

 July 2013 - December 2017

 Member, Clinical and Translational Scientific Institute (CTSI), Tufts Medical Center

 Member

 July 2013 - December 2017

Director, Tufts Cancer Center at Tufts Medical Center, Boston, MA

 Director

 April 2014 – December 2017

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Associate Director for Clinical Services

January 2018 – current

Oncology Service Line, RWJBarnabas Health

Medical Director

January 2018 – current

Lymphoma Program, Division of Blood Disorders

Director

January 2018 – June 2021

Rutgers Biomedical Health Sciences (RBHS) at Rutgers University

Associate Vice Chancellor, Clinical Innovation and Data Analytics

June 2021 – current

Combined Medical Group (physician organization), RWJBH and Rutgers Health

Oncology Lead

July 2021 – current

**PRIVATE PRACTICE:** n/a

**LICENSURE:**

 Internal Medicine, American Board of Internal Medicine / 8-24-2009

 Hematology, American Board of Internal Medicine / 11-13-2023

Medical Oncology, American Board of Internal Medicine / 11-12-2023

 **DRUG LICENSURE:**

CDS: ME0820820H (Massachusetts); D11146800 (New Jersey) / *10/31/2018*

 DEA: BE6055176 / 8-31-2019

**CERTIFICATION:**

 State of Illinois, Licensed Physician *(#036-098507) / 8-24-2011*

 State of Massachusetts, Licensed Physician *(#246238) / 8-24-2019*

State of New Jersey, Licensed Physician (#25MB10237400) */ 6-30-2019*

**MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:**

 American Society of Clinical Oncology

 Member

 2000 - present

 American Society of Hematology

 Member

 2000 - present

Eastern Cooperative Oncology Group

Core Member of Lymphoma Committee

2001 - present

American Society of Hematology (ASH) ABIM maintenance for certification: Practice Improvement Modules (PIMs) in lymphoma and co-author for 2018 ASH-SAP (Hodgkin Lymphoma) Disease expert

2012 - present

**HONORS AND AWARDS:**

Bill Bradley Academic All-American

NCAA Division II Basketball

1989

Magna cum laude, Biochemistry,

Saint Joseph’s College

1991

Sigma Sigma Phi (National Osteopathic Honor Society)

1994

Intern of the Year

Lutheran General Hospital (chosen by fellow housestaff as the physician they would most want to take care of their mother or father)

1996-1997

Compassion Awards (x 4)

Lutheran General Hospital

1996-2000

First Place, Department of Internal Medicine Competition

Lutheran General Hospital, Clinical Vignette, Oral Presentation for ACP Illinois Chapter

1998

Selected Fellow,

AACR/ASCO Methods in Clinical Cancer Research Meeting

2002

Translational Research Award (most outstanding research presentation),

ECOG’s Young Investigators’ Clinical Scientist Symposium

2002

Compassionate Care Annual Award

The Woman’s Board of Northwestern Memorial Hospital

2005

Annual Excellence in Teaching Award

Department of Medicine, Northwestern University

2008-9

Teaching Attending of the Year

Division of Hematology/Oncology, Northwestern University

2009

Associate Editor

*British Journal of Haematology*

2012

Leadership Academy (certificate)

Tufts University School of Medicine and The Heller School for Social Policy and Management, Brandeis University; Boston, MA

2014

Nominated to the Scientific Advisory Board (SAB), *1 of 45 Nationally elected members*

Lymphoma Research Foundation (LRF)

2014 (re-elected to 5-year term 2019)

Advisory Panel to Vice President Joseph Biden *(for Cancer Moonshot effort)*

Naval Observatory, Washington, DC

December 1st, 2015

Nominated: Fellowship of the American College of Physicians (FACP)

2016

Named the Chan Soon-Shiong Endowed Scholar in Precision Medicine

Tufts Medical Center, Boston, MA

2016

Named Top Doctor

via *Boston Magazine*

2017

Named Top Doctor

East Coast, *Castle Connolly*

2018 and 2019

Mission Chair

Leukemia and Lymphoma Society (LLS) annual “Light The Night” Event

Mercer County Park, November 3rd, 2018, Princeton, NJ

Grand Marshall

Lymphoma Research Foundation (LRF) New York Walk

New York, New York, June 12th, 2019

New Jersey Top Doctor in Cancer Care

Castle Connolly Medical Ltd (*Jersey’s Best* magazine)

2019

Re-elected to the Scientific Advisory Board (SAB), *1 of 45 Nationally elected members*

Lymphoma Research Foundation (LRF)

2019

Top Doctors, New York Metro Area

Connolly Top Doctors

2020

Top Doctor, Hematology

Jersey's Best Magazine

September 2020

New Jersey Top Doctor in Cancer Care

Castle Connolly Medical Ltd (*Jersey’s Best* magazine)

April 2021

**BOARDS OF DIRECTORS/TRUSTEES POSITIONS:**

Elected to Board of Trustees

Leukemia and Lymphoma Society (LLS), New Jersey Chapter

2019

**SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:**

Office of Orphan Products Development, FDA/NIH. Rockville, MD

Ad Hoc panel/primary reviewer

June 25th, 2008

Office of Orphan Products Development, FDA/NIH. Rockville, MD

Ad Hoc panel/primary reviewer

June 4th, 2009

Office of Orphan Products Development, FDA/NIH. Rockville, MD

Ad Hoc panel/primary reviewer

November 30th, 2009

Office of Orphan Products Development, FDA/NIH. Rockville, MD

Ad Hoc panel/primary reviewer

May 24th, 2011

Chair, Hematology Review Panel (*Chair*), VA Scientific Merit R01 Review Panel, NIH and NCI

Term: November 2012 through October 2016

National Cancer Institute (NCI) Special Emphasis Panel (*Co-Chair*), NCI SPORE (P50) Review Panel

01/27/2021 to 01/28/2021

**SERVICE ON MAJOR COMITTEES:**

***A. International***

The International Primary CNS Lymphoma (PCNSL) Collaborative Group (IPCG), member

December 2007 - present

Leukaemia & Lymphoma Research; London, England and Edinburgh, Scotland

October 2011

Clinical Trials Awards & Advisory Committee; The National Cancer Research; London, England, United Kingdom panel

February 2012

European Society for Medical Oncology (ESMO) Competence in Lymphoma (CCL) Instructor/Faculty: Post-Transplant Lymphoproliferative Diseases (PTLD); 2013

Faculty for European School of Oncology and Ulm University. Certificate of Competence in Lymphoma (CCL) programme. Post-transplant lymphoproliferative disorder.

2013-2014

Hematological malignancies in pregnancy; International Consensus Conference, UZ Louven, Louven,

Belgium

May 2014

Co-Chair, International Data Safety Monitoring Committee (DSMC), Juliet, Pivotal phase 2 study of tisagenlecleucel (CTL019) CAR T-cell therapy in relapsed/refractory DLBCL

May 2017 – January 2019

Chair, International Data Safety Monitoring Committee (DSMC) for Pharmacyclics: Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma; and A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase 3 Study of Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

January 2018 – present

Chair, International Data Safety Monitoring Committee (DSMC) for Novartis (protocol CCTL019H2301): Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA); March 2019 to present

March 2019 – present

Member, Data Safety Monitoring Committee (DSMC) for AbbVie for study: Treatment of Patients Hospitalized for COVID-19 Infection and Pulmonary Distress with Ibrutinib; April 2020 to present.

International Symposium on Hodgkin Lymphoma (ISHL), German Hodgkin Study Group; Cologne, Germany; Scientific Committee Member, 2019 to present

***B. National***

Eastern Cooperative Oncology Group, *Core Committee Member*: Lymphoma

July 2001 - present

Primary panel member of NCCN (National Comprehensive Cancer Network), Hodgkin

disease/lymphoma, and secondary panel member for non-Hodgkin’s lymphoma

March 2007 – December 2010

Primary/voting member, ECOG Laboratory Science Advisory Committee

July 2009 - 2016

Clinical Trial Design & Development Working Group, Quantitative Imaging Network (QIN) with CTEP

and NIH

July 2010 - 2017

Primary/voting member, Developmental Therapeutics committee, ECOG

June 2010 - 2016

Hodgkin Lymphoma Working Group, primary member, NIH/NCI Steering Committee Subgroup

April 2011 - present

Chair, New England Lymphoma Rounds Steering Committee, Lymphoma Research Foundation;

May 2011 - 2017

Disease expert, American Society of Hematology (ASH), ABIM maintenance for certification: Practice

Improvement Modules (PIMs) in lymphoma. 2012-2016

NantKwest QUILT - Quantitative Integrated Lifelong Trials; Cancer MoonShot 2020; Founding

Institution and Advisory Board

December 2015 – February 2017

Group Leader, Lymphoma Research Foundation (LRF), Lymphoma Research Foundation Clinical Research Mentoring Program (LCRMP); Washington, DC; March 14-18, 2017

National Co-Chair and speaker, 2017 North American Educational Forum on Lymphoma. Lymphoma Research Foundation (LRF), October 20-22nd, Brooklyn, NY

New York Lymphoma Rounds, Steering Committee, Lymphoma Research Foundation (LRF);

January 2018 - present

Co-chair Lymphoma Research Foundation (LRF), Lymphoma Research Foundation Clinical Research Mentoring Program (LCRMP); Phoenix, Arizona; March 2018 and March 2019

Children’s Oncology Group (COG), member

June 2018 – present

Philadelphia Lymphoma Rounds, Steering Committee, Lymphoma Research Foundation (LRF);

November 2018 – present

Co-chair, Lymphoma Working Group for the Big 10 Cancer Research Consortium; April 2019 – present

AYA Oncology Drug Development Panel; Lymphoma Research Foundation (LRF) 2019 Adolescent and Young Adult Workshop; May 2019; Chicago, IL

Vice Chair, ECOG/ACRIN Lymphoma Committee, NCI; January 2020 – present

LRF COVID-19 and Lymphoma Panel Member; March 2021 – present

***C. Medical School/University***

Primary reviewer (voting) member, Institutional Review Board, The University of Massachusetts Medical

School

April 2011 – July 2013

Co-Representative, Scientific Council, The University of Massachusetts Medical School

June 2011 – July 2013

***D. Hospital/Service Line***

Coordinator, Chemotherapy safety committee, Northwestern Memorial Hospital

June 2005 – December 2008

Founder and Co-Chair, Tufts Cancer Center Pharmacy and Therapeutics (P&T) Committee, Tufts Medical

Center, Boston, MA

September 2013 – December 2017

EMR Transition Executive Committee; RWJUH and Rutgers CINJ; February 2018 to present

Founding Member and Co-Chair, Rutgers Cancer Institute of New Jersey, Pharmacy and Therapeutics (P&T) Committee, Robert Wood Johnson University Hospital, New Brunswick, NJ

March 2018 – present

Horizon Blue Cross Blue Shield of New Jersey, P and T committee (member representing RWJUH and Rutgers CINJ); April 2018 – April 2020

Chair, Clinical Advisory Leadership Council, Oncology Service Line, RWJBH April 2018 to present

Founding Chair and Executive Planning Committee, Cardio-Oncology Program; RWJBH and Rutgers CINJ; July 2018 to present

CINJ Ambulatory Executive Committee; Founding Member and Co-Chair; Rutgers Cancer Institute of New Jersey and RWJBUH; August 2018 to present

Executive Steering Committee; Huron Consulting; RWJUH and Rutgers CINJ; August 2018 to 2019

Co-Chair, US News World Report Task Force; RWJUH and Rutgers CINJ; September 2018 to present

Founding Director, RWJBH and CINJ Oncology Tele-Medicine Program; December 2018 to present

Director, Virtual Cancer Tumor Boards, Rutgers CINJ and RWJBH Oncology Service Line, February 2019

Director, Hospital-to-Hospital Transfer Program, RWJBH Oncology Service Line; April 2019 to present

Member, RWJBH Rutgers Health Combined Medical Group, Provider Recruitment Review Committee (PRRC)

July 2021 – current

Member, RWJBH Rutgers Health Combined Medical Group, Medical Group Strategic Council

July 2021 – current

***E. Department/Center***

Member, Clinical Protocol Scientific Review Committee (SRC), Rutgers CINJ

November 2018 – Current

Member, Clinical Protocol Scientific Review and Monitoring Committee (CPSRMC), Robert H. Lurie

Comprehensive Cancer Center of Northwestern University

July 2004 – December 2010

Primary/voting member, Data Safety and Monitoring Committee, Robert H. Lurie Comprehensive Cancer

Center of Northwestern University

June 2006 – December 2010

Primary/voting member, Protocol Review Committee and Data Safety and Monitoring Committee, UMass

Memorial Cancer Center and The University of Massachusetts

January 2011 – July 2013

Chair, Cancer Center Mini Symposia Program: Biomarker Discovery and Targeted Therapeutics in Cancer; The University of Massachusetts Center for Clinical and Translational Science, 4th Annual Research Retreat. May 8th, 2013.

Primary/voting member, Protocol Review Committee and Data Safety and Monitoring Committee, Tufts

Cancer Center, Boston, MA

July 2013 – December 2017

Member, Scientific Review Committee (SRC), RWJBH and Rutgers CINJ, August 2018 – Present

EHR Selection Committee, RWJBH, West Orange, NJ

October 2018 – December 2019

Hematology/Oncology GME Workgroup, RWJBH, West Orange, NJ

October 2018 – January 2020

BHMG, Oncology Compensation Steering Committee; RWJBH, West Orange, NJ

November 2018 – January 2020

Co-Chair,Patient Relief FundWorking Group, RWJUH and CINJ, March 2019 – current

Founding Co-Director ofthe RWJBH *Cancer Survivorship Clinical and Research Program/Center of Excellence*

January 2020 – current

Executive Committee and Working Group, Tele-Medicine Program for RBHS and RWJBH

March 2020 – current

Member, Rutgers CINJ and RWJBH Oncology Service Line COVID-19 Taskforce Executive Committee

March 2020 – current

Member, Horizon Blue Cross Blue Shield of New Jersey, Home Infusion Pilot Program, CINJ, NJ

December 2020 – current

***F. Editorial Boards***

*American Journal of Blood Research,* ***Senior Editorial Board (since 2010)***

*Leukemia Research,* ***Editorial Board******(since 2011)*** (1)

*British Journal of Haematology*, ***Associate Editor, since 2014*** for academic year FY19 (i.e., July 2018 through June 2019): 95 total manuscripts assessed/triaged (i.e., 11 letters, 73 full manuscripts, 10 short reports, and 1 state of the art review).

*Journal of Clinical Oncology*, ***Editorial Board (2014-2019)***

*EJHaem*, ***Inaugural Editor in Chief,*** journal launch: December 2019 <https://onlinelibrary.wiley.com/journal/26886146>

***G. Ad Hoc Reviewer***

*Blood* (3 in 2020)

*Cancer Research* (2 in 2020)

*Clinical Cancer Research* (2 in 2020)

*Haematologica* (1 in 2020)

*Journal American Medical Association (JAMA)* (1 in 2020)

*Lancet Oncology* (1 in 2020)

*New England Journal of Medicine* (1 in 2020)

*Journal of Clinical Oncology* (9 in 2020)

**SERVICE ON GRADUATE SCHOOL COMMITTEES:**

Tufts University School of Medicine, Cancer Educational Symposium Committee

January 2016 – 2018

**SERVICE ON HOSPITAL COMMITTEES:** please see above in Section D

**SERVICE TO THE COMMUNITY:**

Co-Chair, Third International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago Section of Hematology/Oncology and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. October 28th, 2005

Co-Chair, Lymphoma and Plasma Cell Disorders Poster Discussion. American Society of Clinical Oncology (ASCO). Atlanta, Georgia, June 2006

Co-Chair, Fourth International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago Section of Hematology/Oncology and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. April 28th, 2007

Co-Chair, Fifth International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago Section of Hematology/Oncology and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. April 26th, 2008

Co-Chair, Sixth International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago Section of Hematology/Oncology and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. April 17th, 2009

Co-Chair, American Society of Hematology (ASH), 50th Annual Meeting. Uncommon lymphomas and supportive care, December 2009

Co-Chair, Seventh International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago Section of Hematology/Oncology and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. April 23rd and 24th, 2010

Co-Chair, Developmental Therapeutics, Lymphoma and Plasma Cell Disorders (Education Session), Tumor Biology, American Society of Clinical Oncology (ASCO). Chicago, IL, June 2010

Co-Chair, Eight International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. April 29th and 30th, 2011

Co-Chair, Ninth International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. April 27th and 28th, 2012.

Co-Chair, Tenth International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. April 26th and 27th, 2013

Faculty member/mentor (Group Leader) for: Lymphoma Research Foundation (LRF) National Mentoring Program (for senior fellows and junior faculty). Phoenix, AZ; February 4th through 8th, 2014

Faculty member/mentor. MIT-Tufts Physician Shadow Program. Boston, MA; March 13th, 2014

Co-Chair, Eleventh International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. May 2nd and 3rd, 2014

Co-Chair, 12th International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. April 24th and 25th, 2015

Faculty member/mentor (Group Leader) for: Lymphoma Research Foundation (LRF) National Mentoring Program (for senior fellows and junior faculty). Phoenix, AZ; February 24th through 28th, 2015

## Chair: 1st Annual Symposium: Applying Precision Medicine to the Treatment of Hematologic Diseases; Tufts University School of Medicine; Boston, MA. May 14th, 2016

Co-Chair, 13th International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. May 16th and 17th, 2016

Co-Chair. Lymphoma Research Foundation (LRF) New England Lymphoma Annual Patient Workshop, May 21st, 2016; Needham, MA

Faculty member/mentor (Group Leader) for: Lymphoma Research Foundation (LRF) National Mentoring Program (for senior fellows and junior faculty). Washington DC, February 27th through March 4th, 2017

Organizing Committee and Chair. Tufts Cancer Center: New England Cancer Moonshot Summit; June 29th, 2016; Boston, MA

## Founding Chair: 2nd Annual Symposium: Applying Precision Medicine to the Treatment of Hematologic Diseases; Tufts University School of Medicine; Boston, MA. April 8th, 2017.

Co-Chair, Lymphoma Research Foundation (LRF) National Mentoring Program (for senior Oncology fellows and junior faculty). Phoenix, Arizona; March 6th to 10th, 2018

Co-Chair, 15th International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. May 4-5, 2018

Program Chair; Harnessing New Targeted Therapies in Hematologic Malignancies; LLS Professional Education Program; October 11th, 2018, Spring Lake, New Jersey

Co-Chair, Lymphoma Research Foundation (LRF) National Mentoring Program (for senior Oncology fellows and junior faculty). Phoenix, Arizona; March 5th to 9th, 2019

Co-Chair, 16th International Ultmann Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. April 2019

Chair, CLL Connection: “Dinner with the Docs”. Via Patient Power (<https://patientpower.info/nj>) for Northern, Central, and Southern, New Jersey (virtual). July 13th, 14th, and 15th, 2020

Co-Chair, 17th International Ultmann (Virtual) Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. August 28th and 29th, 2020

Co-Chair, 18th International Ultmann (Virtual) Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. April 30th and May 1st, 2021

**SPONSORSHIP (Primary Mentorship) OF CANDIDATES FOR POSTGRADUATE DEGREE:**

Primary Mentor: 1st-year Northwestern University, Department of Medicine Resident, Anjeni Keswani, MD- regarding tissue microarray analysis (TMA) survival correlation of Hypoxia-Inducible Factor-Alpha activation in non-Hodgkin's lymphoma and relationship to the thioredoxin- Academic years 2006-2008

Primary Research Advisor/Mentor: Boston University Masters student, Wendy Zedan (Thesis supervisor): Research project: Examination of prognostic factors in very elderly non-Hodgkin’s lymphoma. Academic year: 2009-2010.

Primary Research Advisor/Mentor: University of Massachusetts Medical School medical student, Jacqueline (Tessa) Draper. Research project: Impact of Fatty Acid Signaling in Non-Hodgkin Lymphoma; Academic year 2010-2011.

Primary Research Advisor/Mentor: Asa Clemenzi-Allen, 4th year University of Massachusetts Medical School medical student, Class of 2012; Course: 412: Senior Scholars Research (M4 and M7); and Course: 425: Independent Study/Research; Research project: Survival Improvements in Follicular Lymphoma by Race, Age, Sex, and Socioeconomic Status in the Era of Rituximab (ASCO abstract presented at 2012 ASCO meeting; manuscript published in *Annals of Oncology*); Academic year 2011-2012.

Primary Research Advisor/Mentor: Jennifer Crombie, 4th year University of Massachusetts Medical School medical student, Class of 2012; Course: 412: Senior Scholars Research (M4 and M7); and Course: 425: Independent Study/Research; Research projects: Efficacy and Mechanisms of Action of Organic Arsenic (Darinaparsin) in the Treatment of Hodgkin’s Lymphoma and T-cell Lymphoma (2012 ASH abstract in preparation and manuscript); Academic year 2011-2012.

Primary Research Advisor/Mentor: Jessica (Tessa) Draper, 2nd year University of Massachusetts Medical School medical student Flexible Clinical FCE 381 Student Design: Continuing Work in Lymphoma Research Experience (FCE). Research projects: a) Characteristics and outcomes of extranodal NK/T-cell lymphoma (ENKL): A North American multi-institutional experience (ASCO abstract presented at ASCO 2012 meeting; manuscript in preparation); b) The Impact of Fatty Acid Acquisition on Diffuse Large B-Cell Lymphoma Signaling and Prognosis (Tri-University Danny grant funded; 2 poster presentations at 2012 ASH meeting); c) Outcomes of Patients with Newly Diagnosed Peripheral T-cell Lymphoma Treated with Aggressive Chemotherapy (ASH 2012 and ASCO 2012 poster presentation; one invited review paper published and original peer-review manuscript); Academic years 2011-2012.

Primary Research Advisor/Mentor: Irina Zaretsky, 4th year UMASS medical student, Class of 2013; Course: 412: Senior Scholars Research (M4 and M7); and Course: 425: Independent Study/Research; Research projects: Efficacy and Mechanisms of Action of the 2nd Generation Proteasome Inhibitor, MLN2298, in the Treatment of Hodgkin’s Lymphoma and T-cell Lymphoma Cells and Xenograft Models (2013 Lugano poster presentation; and manuscript in preparation); Academic year 2012-2013.

Primary Research Advisor/Mentor: Robert Cerulli (MD/PhD Candidate/TUSM 4th year Medical Student). Translational laboratory work on Novel BTK inhibitor in DLBCL. Blood/ASH poster presentation ([2014; 124 (21)](http://www.bloodjournal.org/content/124/21): 1772) and “1st Prize” in the 2014 TUSM Medical Student summer research poster competition/symposium. Academic year 2013-2014. Awarded F30 Fellowship 2017.

Primary Research Sponsor/Mentor: Erica Heiden, MBS Candidate, Tufts University; Thesis: Outcomes of Asians with non-Hodgkin lymphoma in Chinatown, Boston; MBS Thesis. Academic year: 2017.

Primary Research Sponsor/Mentor: Patrick Puliti, MD Rutgers Robert Wood Johnson Medical School; MDC 9800, Research in Oncology (translational lymphoma laboratory; September-December 2018)

**SPONSORSHIP (Primary Mentorship) OF POSTDOCTORAL FELLOWS AND FACULTY:**

Primary Research Mentor: Clinical research mentoring of Hematology/Oncology fellow- Muhajid Rizvi, MD for NU 05CC5: Early Epoetin Alfa (Procrit) Treatment to Prevent Bleomycin-induced Pulmonary and/or Anthracycline-induced Cardiac Toxicity: A Randomized Phase II Study in Patients with Lymphoma and Testicular Cancer; Academic year 2004-2005.

Primary Research Mentor: Hematology/Oncology fellow- Olivia Aranha, MD: A Multicenter Phase II Study Incorporating Doxil and Rituximab into the Modified Magrath Regimen for Patients with Newly Diagnosed Burkitt's and Burkitt-like Lymphoma- Academic year 2004-2005 and 2005-2006.

Primary Research Mentor: Laboratory and clinical research mentoring of Hematology/Oncology fellow, Kevin David, MD regarding: a) clinical project for post-transplantation lymphoproliferative disease (PTLD) at Northwestern; and b) laboratory training: oxidative stress and apoptosis in lymphoma; Dr. David accepted position as faculty member at the Cancer Institute of New Jersey (UMDNJ) with specialty in lymphoma; also 4 laboratory and clinical projects: a) clinical project for post-transplantation lymphoproliferative disease (PTLD) at Northwestern; b) laboratory training: oxidative stress and apoptosis in lymphoma; c) translational project studying RAD51 in HDAC inhibitors for treatment of lymphoma; and d) clinical trial research (Combination of bortezomib and rituximab in untreated high tumor burden follicular lymphoma); published original papers in *Journal of Clinical Oncology, British Journal of Heamatology, Clinical Cancer Research* x 2 manuscripts, and 2 additional invited review papers; Dr. David accepted position as faculty member at the Cancer Institute of New Jersey (UMDNJ) with specialty in lymphoma. Academic years 2006-2009.

Primary Research Mentor: Northwestern University resident- Valerie Nelson, MD. Research project: Examination of survival and prognostic factors in elderly Hodgkin disease; poster presentation at 2010 Cologne Hodgkin lymphoma meeting; Academic year: 2009-2010.

Primary Research Mentor: University of Massachusetts Medical School fellow, Deepa Jagadeesh, MD. Research project: T-cell non-Hodgkin lymphoma: prognosis and therapy (retrospective multi-center analysis); also PTLD prognosis and treatment; manuscript/report. Dr. Jagadeesh accepted a faculty position at The Cleveland Clinic, with specialty in lymphoma. Academic year: 2010-2011.

Primary Research Mentor: University of Massachusetts Medical School resident- Austin Kim, MD. Research project: Prognosis of quantitative imaging in lymphoma (retrospective multi-center analysis). Academic year: 2010-2011.

Primary Research Mentor: Laboratory and clinical research training of 2nd-year Northwestern University resident, Lauren Mauro, MD for: a) clinical project for post-transplantation lymphoproliferative disease (PTLD) at Northwestern; and b) laboratory training: oxidative stress and apoptosis in lymphoma- Academic years 2006-2009.

Primary Research Mentor: Austin Kim, MD, 2nd and 3rd UMASS resident, Department of Medicine; Research projects: a) Quantitative metabolic tumor burden in DLBCL and the Impact of Fatty Acid Acquisition on Diffuse Large B-Cell Lymphoma Signaling and Prognosis (Tri-University Danny grant funded; abstract in preparation for 2012 ASH meeting); b) Outcomes of Patients with Newly Diagnosed Peripheral T-cell Lymphoma Treated with Aggressive Chemotherapy (2012 ASH and Lugano 2013 poster presentations and manuscript in preparation); Academic years 2011-2012 and 2012-2013.

Primary Research Mentor: Xiuning Li, MD, 2nd year UMASS Resident, Department Medicine. Research projects: a) Quantitative metabolic tumor burden in DLBCL and the Impact of Fatty Acid Acquisition on Diffuse Large B-Cell Lymphoma Signaling and Prognosis (Tri-University Danny grant funded; 2 ASH 2012 and Lugano 2013 poster presentations and manuscript in preparations); b) Outcomes of Patients with Newly Diagnosed Peripheral T-cell Lymphoma Treated with Aggressive Chemotherapy (2012 ASH and Lugano 2013 poster presentations and manuscript in preparation); Academic years 2011-2012.

Primary Research Mentor: Deepa Jagadeesh, 3rd year fellow, UMASS Division of Hematology/Oncology. Primary faculty mentor (Dr. Jagadeesh accepted a faculty position at The Cleveland Clinic, with specialty in lymphoma); Research projects: a) Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era (oral presentation at ASH 2011 and manuscript published in *American Journal Transplantation*); Academic year 2011-2012.

Primary Research Mentor: Nahida Islam, 2nd year fellow, UMASS Division of Hematology/Oncology; Research projects: Primary breast lymphoma: outcomes and prognostic factors in the contemporary era (ASH 2012 abstract in preparation); b) The incorporation of rituximab and liposomal doxorubicin into CODOX-m/IVAC for untreated Burkitt’s lymphoma:  Final results of a prospective multicenter phase II study (poster presentations at ASCO 2012, UMass Annual Research Retreat 2013, and Lugano 2013; original manuscript in preparation); Academic years 2011-2012 and 2012-2013.

Primary Research Mentor: Ravi Dashnamoorthy, PhD, The University of Massachusetts Medical School; Research projects: Efficacy and Mechanisms of Action of Organic Arsenic (Darinaparsin) in the Treatment of Hodgkin’s Lymphoma and T-cell Lymphoma (2012 ASH abstract in preparation and manuscript in preparation); b) Efficacy and Mechanisms of Action of the 2nd Generation Proteasome Inhibitor, MLN2298, in the Treatment of Hodgkin’s Lymphoma and T-cell Lymphoma Cells and Xenograft Models; c) The Impact of Fatty Acid Acquisition on Diffuse Large B-Cell Lymphoma Signaling and Prognosis (Tri-University Danny grant funded; poster presentations at ASH 2012 (x 4) and Lugano 2013 (x 2); and 3 original manuscripts in preparation); Academic years 2011-2012 and 2012-2013.

Primary Research Mentor: Muthalagu Ramanathan, MD, Assistant Professor of Medicine (UMASS faculty, Division of Hematology/Oncology) for the UMASS Junior Faculty Development Program; and for Clinical Trials for the Treatment of Hematologic Malignancies; Academic years 2011-2012 and 2012-2013. During this time, Dr. Ramanathan opened/activated 6 clinical trials (Cooperative group, Industry, and Investigator-initiated studies).

Primary Research Advisor and Mentor: Syed Quadri, MD, Assistant Professor of Surgery (UMASS faculty, Division of Surgical Oncology) for the UMASS Junior Faculty Development Program; and for Clinical Trials for the Treatment of Hematologic Malignancies; Academic year 2012-2013. Dr. Quadri has developed a sophisticated health outcomes (cost) and patient self-reported outcomes regarding early-stage resectable lung cancer.

Primary Research Mentor: Jaya Sharma, MD (Tufts MC Hematology/Oncology fellow). Laboratory/translational research: investigation of the lethality and importance of suppressing the MAPK pathway with MEK small molecule inhibitors alone and with rational combinations; clinical research project: Impact of routine surveillance imaging (RSI) on outcomes in patients with diffuse large B-cell lymphoma (DLBCL). Academic years 2013-2015.

Primary Research Mentor: Urvi Shah, MD (Tufts MC Internal Medicine Resident); published report Paraneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative disorder. Ann Hematol. 2015; 94:893-4.

Primary Research Mentor: Aditi Puri, MD (Tufts MC Internal Medicine Resident); collaborating on project and presented at ASH 2015 annual research symposium: [Hepatitis B (HBV) Screening in Patients Receiving Rituximab: A Comprehensive Analysis Including Comparison of Adherence By Oncologists and Non-Oncologists](http://www.bloodjournal.org/content/124/21/2595) (abstract 2595).

Primary Research Mentor: Athena Kritharis, MD (Tufts MC Hematology/Oncology fellow). a) Comparative Oncology Analyses of Genomics and Proteomics in Lymphoma- Translational Research. Resulted in Blood/ASH) Poster presentation ([2014; 124 (21)](http://www.bloodjournal.org/content/124/21): 1703) and ECOG Young Investigator Oral Presentation October 2014; Gray Zone Lymphoma (GZL) clinical project, resulted in Blood/ASH poster 2014; 124:3019. A Comparative Oncology Analysis of Canine T-Cell Lymphoma (TCL): Immunohistochemical Study and Next Generation Sequencing for Protein Analysis and Genomic Target Discovery- translational research for Blood/ASH poster 2015; 126:1234. Academic years 2013-2015.

Primary Research Mentor: Michael Coyle, MD (Tufts MC Hematology/Oncology fellow). Laboratory/translational research: Transcriptomic profiling of response to PI3K inhibition by BKM120 in lymphoma cells. Poster presentation: Genome-Wide Analysis Reveals MYC-Dependent Cell Death and Identifies Predictive Biomarkers of Ixazomib Sensitivity, ASH 2014; 124:3120. The PI3 Kinase (PI3K) Inhibitor, Buparlisib/BKM120, in B-Cell, T-Cell and Hodgkin Lymphoma Cell Lines: Cell Death Studies and Examination of Genomic Pathway Analyses Via a Systems Biology Approach, ASH 2015; 125:1555. Academic years 2013-2017.

Primary Research Mentor: Frank Passero, MD (Tufts MC Hematology/Oncology fellow). Laboratory/translational research: Novel-novel combinatorial therapy with proteasomal inhibitor via a systems biology approach. Poster presentation: The Proteasome Inhibitor, Ixazomib, Combined with Novel Drug Combinations in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Identification of Key Genes and Signaling Pathways Via a Novel Systems Biology Approach. ASH 2015; 125:2753. Academic years 2014-2017.

Primary Research Mentor: Gurbakhash Kaur, MD (Tufts MC Internal Medicine Resident); published paper: [Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience](http://www.bloodjournal.org/content/128/18/2199); Blood 2016 128:2199-2205

Research co-mentor: Julie Fu, MD (Tufts MC Internal Medicine Fellow); presented poster at ASH annual research symposium and manuscript “in press”: Assessing the Risk of Cardiac Toxicity after Contemporary Treatment for Hodgkin Lymphoma (HL): A Multidisciplinary Systematic Review.

Primary Research Mentor: Abhigna Kodali, MD; Tufts MC Internal Medicine Resident; Project: Maintenance Rituximab or Observation after Frontline Treatment with Bendamustine-Rituximab (BR) for Follicular Lymphoma: A Real World Analysis Across 13 US Cancer Centers; abstract submitted to American Society of Hematology (ASH) 2017 symposium.

Committee Member/Sponsor, Thesis Dissertation, Yasin Kaymaz, PhD; Genomic and Transcriptomic investigation of Endemic Burkitt lymphoma and Epstein Barr Virus; UMass Medical School, June 2017; Worcester, MA.

Primary Research Mentor: Sneha Purvey, MD (Tufts MC Hematology/Oncology fellow). Laboratory/translational research: CD19 Target Activated Natural Killer (CD19.TaNK) Cellular Therapy. ASH abstract- CD19 Target Activated Natural Killer (CD19.TaNK) Cellular Therapy: A Novel immunotherapeutic Approach to the Treatment of Non-Hodgkin Lymphoma (NHL). Blood (ASH) 2016; 128 (22):4174; also selected for oral presentation at ECOG Young Investigators annual meeting 2016. Academic years 2015-2018

Primary Research Mentor: Kevin David, MD (Rutgers Hematology/Oncology faculty). Multiple database and clinical trial projects: large-scale molecular sequencing consortium study (i.e., >10,000 samples) in collaboration with Rutgers Pathology (Dr Lauri Goodell); high grade B cell lymphoma retrospective analysis; clinical and prognostication study of PTCL, co-led by Rutgers and Cleveland Clinic; clinical and prognostication study of gamma delta cutaneous T-cell lymphoma, co-led by Rutgers and MSKCC; and chemotherapy following checkpoint inhibitor retrospective study.

Research mentor: Mansi Shah, MD (Rutgers CINJ Hematology/Oncology Fellow); North American Practice Patterns in PET-2 Positive Classical Hodgkin Lymphoma: A Multicenter Observational Analysis; 2019 ASH abstract submission/poster presentation.

Research mentor: Jordan Carter: MD (Rutgers CINJ Hematology/Oncology Fellow); Outcomes of Current Regimens in Elderly Patients with Classical Hodgkin Lymphoma; 2019 ASH abstract submission/poster presentation; separate project on Genomic Ancestry in B Cell Lymphoid Malignancies, ASH 2020 abstract; Radiation-Based Approaches as an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma, ASH 2020 abstract.

Research mentor: Catherine Wei, MD (Rutgers CINJ Hematology/Oncology Fellow); Outcomes and Prognostication of Burkitt Lymphoma in the Modern Era; 2019 ASH abstract submission x 2 oral presentations; EHA 2020 oral presentation; 2 ASH 2020 oral presentations; and 4 peer-reviewed publications (Real World Outcomes in Burkitt Lymphoma [Blood]; The Burkitt Lymphoma International Prognostic Index [JCO]; CNS outcomes in BL [Haematologica]; Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma [Blood Advances]).

Research mentor: Mansi Shah, MD (Rutgers CINJ Hematology/Oncology Fellow); Environmental Sars-Cov-2 Surface Testing in Outpatient and Inpatient Hematology/Oncology Settings; ASH 2020 abstract and peer-reviewed publications

Research mentor: Kevin David MD (Rutgers CINJ mid-career faculty); Primary CNS Lymphomas in Older Patients; ASH 2020 oral presentation.

**TEACHING RESPONSIBILITIES:**

*A. Lectures or Course Directorships*

Hematology Lakeside VA clinic, Primary staffing attending supervising fellows and housestaff (medical students and residents) at weekly; August 2003 through July 2006; 50 hours/year

Northwestern University Feinberg School of Medicine; Hematology/Oncology Fellowship Core lecture series (Hematology/Oncology Emergencies) and Conference lectures (Lymphoma x 3 annual lectures), 2003-2010; 10 hours/year

Northwestern University Feinberg School of Medicine; Hematology/Oncology Internal Medicine Core lecture series (Hematology/Oncology Emergencies), 2007-2010; 5 hours/year

Northwestern University Feinberg School of Medicine (2 annual lectures), Annual Malignant Hematology Lectures for 1st and 2nd year Medical Students, Scientific Basis of Medicine (SBM), 2003-2010; 5 hours/year

Northwestern University Outpatient Hematology/Oncology clinic supervision: 1st year and 4th year Medical Students, 2007-2010; 0 1hours/year

Northwestern University Feinberg School of Medicine, Hematology/Oncology Board Review- Step 1, 2nd year Medical Students, 2008-2010; 4 hours/year

The University of Massachusetts Medical School, Hematology/Oncology Fellowship Core lecture series (Hematology/Oncology Emergencies) and Conference lectures (Lymphoma x 4; annual lectures), 2011-2013; 5 hours/year

The University of Massachusetts Medical School, Human, Defense, and Blood (HDB) course, medical students (1st year). Two lectures: Non-Hodgkin’s lymphoma and Hodgkin disease/lymphoma (annual x 2). 2011-2013; 5 hours/year

Tufts University School of Medicine, Hematology/Oncology Course, second-year medical student: Introduction to Hematologic Malignancies; 2013-present; 4 hours/year

Cancer Biology Concentration of the CMDB PhD program; “The OMICS of Lymphoid Malignancies”, 2016; 3 hours/year

Tufts University School of Medicine (TUSM), Creator and Speaker: Demystifying Cancer Clinical Trials training series/collaboration with Tufts CTSI educational series: <http://www.tuftsctsi.org/events/demystifying-cancer-clinical-trials/>; 2016; 10 hours/year

Rutgers Robert Wood Johnson, Hematology/Oncology Fellowship Core lecture series (Lymphoma x 4; annual lectures), 2018 – present; 5 hours/year

Targeted Therapeutics in Lymphoid Malignancies. Genomics in Cancer; Therapeutics (GCT), Rutgers University, RBHS-Robert Wood Johnson Medical School, 2019 and 2020

B. Research Training (other than Primary Mentorship)

*Post-Doctoral Fellows:*

Research Mentor: Clinical research mentoring of Hematology/Oncology Fellow: Brett Brinker, MD for NU 06H1. A Phase II Trial of Combination Bortezomib and Rituximab as Front-line Therapy for Low-grade Non-Hodgkin Lymphoma. Academic Year: 2005-2006.

Research Mentor: Hematology/Oncology fellow, Sairah Ahmed, MD regarding 1 laboratory and 1 clinical project: a) clinical trial of SIM-301 glutathione depleting agent in the treatment of lymphoma; b) regulation of cellular CD20 by HIF in lymphoma; published 2 invited review papers; Dr. Ahmed accepted position at MDACC for faculty position in stem cell transplantation. Academic year 2008-2009.

Clinical research mentoring of Hematology/Oncology fellow- Jessica Altman, MD: A Phase II Study Incorporating Motexafin Gadolinium (MGd) into High-dose Methotrexate (MTX)-Based Chemo-immunotherapy and Radiation for Patients with Newly diagnosed Primary CNS Lymphoma; and Phase I/II Trial of Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma (resulted in publication); Dr. Altman accepted position as faculty member at Northwestern University in leukemia. Academic year 2004-2005.

Clinical research mentoring of Hematology/Oncology fellow: Lisa Baddi, DO: NU04S1, Open Label Multicenter Phase II Study of Bevacizumab for the Treatment of Angiosarcoma; published peer-reviewed original manuscript in *Annals of Oncology*; Academic year 2004-2005.

Research Mentor: Northwestern University residents- Taylor Ortiz, MD, and Mrinal Gounder, MD. Analysis of 10 years of Hodgkin's disease patients treated at Northwestern University; poster presentation at 2006 ASCO meeting and published original paper in *British Journal of Heamatology*; Academic years: 2004-2006.

Clinical research mentor of Hematology/Oncology fellow: Jeffrey Cilley, MD: Retrospective analysis of last 150 Hodgkin's disease patients treated at Northwestern University (over last 12 years); poster presentations at 2006 ASCO and 2010 ASH meetings; published original paper in *British Journal of Heamatology*; Academic year 2005-2006.

Research Mentor: Hematology/Oncology fellow, Ken Carson, MD regarding 3 projects: 1) Progressive Multifocal Leukoencephalopathy Associated with Rituximab Treatment of B-Cell Lymphoproliferative Disorders; 2) Clinical research/trial in lymphoma (PCI-24781 HDAC inhibitor for relapsed/refractory lymphoma); and 3) Hepatitis B and C reactivation in lymphoma; Dr. Carson accepted position as faculty member at Washington Universtity with specialty in lymphoma. Academic year 2007-2008.

Research Mentor: Northwestern University fellow, Rupali Roy, MD. Research project: Primary CNS PLTD: outcomes and prognosis (retrospective multi-center analysis); also Examination of survival and prognostic factors in very elderly non-Hodgkin lymphoma; published original papers in *Leukemia and Lymphoma and American Journal of Transplantation*; Dr. Roy accepted faculty position at the University of Virginia with specialty of leukemia. Academic year: 2010-2011.

Research Mentor: Northwestern University resident- Jessica Yarber, MD. Research project: Pregnancy and Lymphoma: management and prognosis; poster presentations at 2010 Cologne Hodgkin Lymphoma meeting and published original paper in *Annals of Oncology*; Academic year: 2010-2011.

Research Mentor: Northwestern University fellow, Joy Feliciano, MD. Research project: Examination of survival and prognostic factors in very elderly non-Hodgkin lymphoma; poster presentations at 2010 ASH, 2011 ASCO, 2011 Lugano, and 2011 ASH meetings; manuscript published in *British Journal of Haematology*; Dr. Feliciano accepted faculty position at the University of Maryland with specialty of lung cancer. Academic year 2010-2011.

Research Mentor: Bradley Switzer, MD; Hematology/Oncology Fellow. University of Massachusetts Lymphoma Research Foundation, Oral Presentation: Post Transplant Lymphoproliferative Disorders; Academic year 2012-2012.

**CLINICAL RESPONSIBILITIES:**

 Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center (Chicago, IL), 2003 to 2011: inpatient bone marrow transplant and leukemia/lymphoma attending service 12 weeks/year; outpatient clinic dedicated to lymphoid malignancies 5 sessions/year

 The University of Massachusetts Medical School and UMass Memorial Cancer Center (Worcester, MA), 2011 to 2013: inpatient bone marrow transplant and leukemia/lymphoma attending service 8-10 weeks/year; outpatient clinic dedicated to lymphoid malignancies 4 sessions/year

 Tufts Medical Center and Tufts University School Of Medicine and Tufts Medical Center (Boston, MA), 2013 to December 2017f: inpatient bone marrow transplant and leukemia/lymphoma attending service 8 weeks/year; outpatient clinic dedicated to lymphoid malignancies 3 sessions/year

Rutgers Cancer Institute of New Jersey and Division of Blood Disorders (New Brunswick, NJ); inpatient leukemia/lymphoma service 4 weeks/year and 3 sessions/week of outpatient clinic dedicated to lymphoid malignancies

METRICS: *Programmatic*: new outpatient lymphoma consults at RWJUH/CINJ (New Brunswick) increased 39% from FY18 to FY19 (increased 63% from FY17 to FY19); this represents the largest program and programmatic growth at CINJ; *Individual*: YTD (June FY20): Clinical FTE 0.62 (actual), 0.3(target) (imputed:reported 206%); Quality: Progress Notes within 7 days: 98%; Progress Notes within 30 days: 99%

**GRANT SUPPORT:**

**A. Principal Investigator (PI or Multi-PI)**

***Non-Clinical Trial (bolded italics: ongoing/active)***

1. K23 CA109613-A1, NIH/NCI ; Title: Targeting the Mitochondria to Treat Lymphoma; Role: PI; 6/1/05 - 5/31/10 Yearly funding: $131,465 (total: $634,780)
2. R03 CA139576-01; NIH/NCI; Title: Impact of Lifestyle with Tumor Pathways and Microenvironment on Lymphoma Survival; 7/1/09 - 12/31/2011; Total costs: $195,378
3. Millennium Pharmaceuticals, Inc; Title: The Examination of MLN2238 Alone and Combined with Rational Novel Drug Combinations in the Treatment of Jurkat, HH, and Hut78 Lymphoma Models; Role: PI; 8/1/2013-7/31/2014; direct costs: $74,250
4. UMass/Dartmouth/Vermont Cancer Centers Collaborative Research; Title: The Impact of Fatty Acid Acquisition on Diffuse Large B-Cell Lymphoma Signaling and Prognosis; 10/01/11-9/30/13; Total costs: $240,000
5. T32 CA09429; NIH/NCI; Title: Research Training in Oncology; 09/01/1981 – 06/30/2015; Role: Principal Investigator; annual direct costs: $1,326,645
6. 3V Biosciences, Inc; Title: The Lipid Addiction of Diffuse Large B-cell Lymphoma (DLBCL) and Potential Treatment Strategies with Novel Fatty Acid Synthase (FASN) Small Molecule Inhibitors; Role: PI; 02/08/2016 – 02/07/2017; direct costs: $74,250
7. Infinity Pharmaceuticals; Title: Investigating the efficacy and mechanisms of cell death with the novel PI3K inhibitor IPI-145 in Hodgkin Lymphoma and T-cell lymphoma cells; Role: PI; 05/01/2015-08/31/2016; direct costs: $36,185
8. Tufts Cancer Center Pilot Project Award Program; Title: Pitfalls, Opportunities, and Implications of Dietary Fat in Targeting Fatty Acid Metabolism in Diffuse large B cell lymphoma; Role: PI; 04/01/2016 - 03/31/2017; direct costs: $15,000
9. Takeda Oncology Hematologic Malignancies Fellowship; Millennium for Division of Hematology/Oncology at Tufts Medical Center; Role: PI; 05/01/2015–04/30/2017; Direct costs: $220,000
10. R01 CA164311-01A1; NIH/NCI; Title: MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm. Role: Multi-PI (with Ron Gartenhaus, Maryland); 08/01/2012 – 08/31/2017; Total costs: $1,654,700
11. Tufts Pilot Funding; Title: A Proof of Concept Pilot Study Evaluating the Safety and Efficacy of a Novel P13K Inhibitor, BKM120, in Dogs with Lymphoma; 1/04/2017 – 12/31/2017; $30,000
12. Tesaro, Inc; Title: Targeting PD1 Pathway in Lymphoma; Role: PI; 02/08/2016 – 02/31/2017 direct costs: $148,500
13. Radiological Society of North America (RNSA). RNSA Satellite Site for: title Medical Image Share Satellite Site Project in Lymphoma; Role: PI 12/10/13-12/31/17; Direct costs: $11,400
14. Tufts CTSI; Title: Determining antibody treatment sensitivity in B cell lymphoma by novel microfluidics-based NK cell immunogenicity platforms; Role: Multi-PI; 5/1/2017-12/30/2017; $30,000
15. Targeting the PD-1 pathway in DLBCL; Industry laboratory grant via Tesaro (July 2018 to December 2019): $77,850 (role: PI)
16. R33 CA223908-01; NIH; Title: Determining treatment sensitivity in B cell lymphoma by novel microfluidics-based NK cell immunogenicity platform; Role: Multi-PI (with Northeastern and Duke University); 05/01/2018 – 04/30/2021; total direct costs: $966,108.
17. **Leukemia and Lymphoma Society (LLS) Translational Research Program (TRP); *“Delineation of the molecular heterogeneity underlying treatment failure in follicular lymphoma”; Role: Multi-PI (with Dr. Robert Kridel at Princess Margaret Cancer Centre); 07/01/2019 to 06/30/2022; total direct costs: $600,000.***

***Clinical Trial Related,*** *investigator-initiated and pharmaceutical sponsored* ***(bolded italics: active/ongoing)***

1. Investigator-initiated, NU 02U1. A randomized phase III study of Zoledronate bisphosphonate therapy for the prevention of bone loss in men with prostate cancer receiving long-term androgen deprivation. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. Sponsor: Novartis; 2005; Northwestern funding: $234,690.20
2. Investigator-initiated, NU 03Z2. Prospective fertility assessment for men and women receiving 90Yttrium-Zevalin therapy. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. Sponsor: IDEC, Inc; 2005; Northwestern funding: $30,000.00
3. Investigator-initiated, NU DF03H4.  Phase II Study of Campath-1H in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia). Sponsor: Wyeth; 2006; Northwestern funding: $15,000.00
4. Drug PCYC-0221.  Phase II Trial of Motexafin Gadolinium (MGd) in Patients with Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. Sponsor: Pharmacyclic, Inc; 2006 Northwestern funding: $166,969.00
5. Drug PIND35.  A pilot Phase II study to determine the safety and efficacy of the combination of ONTAK (Denileukin Diftitox) with CHOP in peripheral T-cell lymphoma. Sponsor: Ligand Pharmaceuticals; 2006; Northwestern funding: $45,691.34
6. Investigator-initiated, NU 02H8. A phase I/II trial of redox regulation in patients with relapsed or refractory CD20 positive non-hodgkin’s lymphoma: combining 90Yttrium-zevalin and the redox-sensitizing agent, motexafin gadolinium (MGd). Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, 2008. Sponsor: Pharmacyclics and IDEC, Inc; 2007; Northwestern funding: $155,000.00
7. Investigator-initiated, NU 04H4. A Phase I/II Trial of Combination Bortezomib(VELCADE®) and Gemcitabine Therapy for Patients with Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin’s Lymphoma. Status: IRB-approved, (multi-institution trial: University of Chicago). Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. Sponsor: Lilly Inc., and Millennium; 2007; Northwestern funding: $222,500.00
8. NCI MSK2795.  A Phase II Study of PS-341 (bortezomib) in Low Grade Lymphoproliferative Disorders. Sponsor: Millennium; 2007; Northwestern funding: $234,690.20
9. DRUG MDX1401-01, A Phase 1, Open-label, Dose Escalation, Multidose Study of MDX-1401 Administered Weekly for 4 Weeks in Patients with CD30-positive Refractory/Relapsed Hodgkin's Lymphoma. Sponsor: Medarex; 2008; Northwestern funding: $237,248.44
10. Investigator-initiated, NU 04S1, An Open Label Phase II Study of Bevacizumab for the Treatment of Angiosarcoma. Status: IRB-approved (multi-institution trial: MD Anderson, Mayo Clinic, Fox Chase, Yale University). Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. Sponsor: Genentech; 2008; Northwestern funding: $120,430.20
11. Investigator-initiated, NU 06H2. A Multicenter Phase II Study Incorporating Doxil and Rituximab into the Magrath Regimen for HIV-Negative and HIV-Positive Patients with Newly Diagnosed Burkitt’s and Burkitt-like Lymphoma. Status: IRB-approved (multi-institution trial: University of Chicago, Loyola University, Rush University). Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. Sponsor: Ortho-Biotec. Northwestern funding; 2009; $188,666.92
12. DRUG CC-5013-NHL-005. A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lenalidomide (Revlimid®) in Combination with Dexamethasone in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Sponsor: Celgene; 2009; Northwestern funding: $108,259.00
13. DRUG GEM012, A Phase I/II Study of Obatoclax Mesylate (GX15-070MS) Administered in Combination with Bortezomib to Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL). Sponsor: Gemin X; 2009; Northwestern funding: $126,215.31
14. DRUG SG035-0004, A Phase 2 study of SGN-35 in treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma; 2009; Northwestern funding: $89,820.48
15. Investigator-initiated, NU 06H1. A Phase II Trial of Combination Bortezomib and Rituximab as Front-line Therapy for Low-grade Non-Hodgkin’s Lymphoma. Status: IRB-approved (multi-institution trial: University of Miami, Fox Chase). Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. Sponsor: Millennium; 2009; Northwestern funding: $150,917.00
16. Investigator-initiated, NU 05H7. A Pilot Study Incorporating Motexafin Gadolinium (MGd) into High-dose Methotrexate (MTX)-Based Chemo- immunotherapy and Radiation for Patients with Newly diagnosed Primary CNS Lymphoma. Status: IRB-approved. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. Sponsor: Northwestern University; 2009; Northwestern funding: Cancer Center pilot trial (no external funding; internal pilot funds)
17. DRUG HQP-1004-EB-03, A Phase 2a Open-Label Multi-Center Study Evaluating HQK-1004 Administered with Ganciclovir and Valganciclovir in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive Lymphoid Malignancies or Lymphoproliferative Disorders; 2009; Northwestern funding: $176,583.53
18. DRUG H6Q-MC-JCBJ. PRELUDE. A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin. Sponsor: Lilly; 2010; Northwestern funding: $110,997.00.
19. DRUG SGL1003: A Phase I Dose Escalation Study of Darinaparsin in Combination with CHOP in Previously Untreated Patients with Lymphomas Who Are Scheduled to Receive CHOP Alone; 2009; Northwestern funding: $89,724.00
20. DRUG M06-814, A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies; 2010; Northwestern funding: $278,658.98
21. DRUG 114-NH-301. A Phase III, Randomized, Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma. Sponsor: Biogen IDEC; 2010; Northwestern funding: $121,112.63
22. PCYC-0403. Phase I/II Dose-Escalation Study of the Pan-Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma. Sponsor: Pharmacyclic, Inc; 2010; Northwestern funding: $279,743.96
23. DRUG AEG35156-204: A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas; 2010; Northwestern funding: $103,484.35
24. DRUG PDX-019: An Open-label, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Lymphoma Patients with Mild, Moderate, and Severe Renal Impairment; 2010; Northwestern funding: $97,690.66
25. DRUG COMPLETE:  Prospective, Longitudinal, Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma; 2010; Northwestern funding: $102,956.64
26. DRUG CC-5013-DLC-001:  A Phase 2/3 Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid) Versus Investigators Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Sponsor: Celgene; 2010; Northwestern funding: $657,394.40
27. Investigator-initiated, A Phase II, Open-Label Study of Bortezomib (Velcade®), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas; 2011; UMASS funding: $112,275
28. Investigator-initiated, A phase I/II Study of Cytoxan, Etoposide, Vincristine, and Prednisone (CEOP) Alternating with Pralatrexate (P) as Front Line Therapy for Patients with Stage II, III, and IV Peripheral T-Cell Lymphoma (PTCL); 2012; UMASS funding: $124,746
29. Drug SPECTRUM: A Randomized, Open Label, Multi Center, Phase II Study of Zevalin (ibritumomab tiuxetan) versus Zevalin and Motexafin Gadolinium (MGD) in Patients with Rituximab Refractory Follicular NHL. Sponsor: Spectrum; 2012; UMASS funding: $228,666
30. Drug PCYC-0403: Dose Escalation Study of the Pan-Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma. Sponsor: Pharmacyclics; 2012; UMASS funding: $56,814
31. S0816. Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Early Interim FDG-PET Imaging (ECOG Co-PI). Sponsor: NCI/CTEP. Opened at UMASS 2011-2013.
32. Investigator-initiated, A Single-Arm Phase II Clinical Trial with the Novel MEK Inhibitor AZD-6244 for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma. Opened at UMASS and Tufts; 2012; Tufts correlative (exclusive of R01 funding above): $40,000
33. DR12GA04915A. A phase II open label multicenter study of efficacy, safety and biomarkers in patients with previously untreated advanced DLBCL treated with GA101 (5072759) in combination CHOP. Sponsor: Genentech; 2012; UMASS funding: $253,068.30
34. Investigator-initiated, NU11L1 (multi-institution trial: University of Nebraska, MSKCC, MD Anderson Cancer Center, Stanford University, Washington University, Ohio State, and Northwestern University). A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients with Untreated Hodgkin Lymphoma; 2010-2012; UMASS funding: $105,552; Tufts funding: $40,184
35. DRPCI32765MCL2001. A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy. Sponsor: Jannsen Research and Development; 2012; UMASS funding: $100,440.10
36. Drug CELGENE: A Phase II Multicenter, Single-Arm, Open-Label Study to Determine the Efficacy and Safety of Single-Agent, Lenalidomide (Revlimid®) in Subjects with Mantle Cell Non-Hodgkin's Lymphoma who have Relapsed or Progressed After Treatment with Bortezomib or are Refractory to Bortezomib. Sponsor: Celgene; 2013; UMASS direct funding: $126,126
37. Drug COMPLETE:  A Prospective Longitudinal Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma (PTCL); 2013; UMASS direct funding: $36,771
38. Drug C14011: MLN8237 A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated Rituximab and Vincristine. Sponsor: Millennium; 2013; UMASS direct funding: $271,968
39. DR11MLNC14011. Clinical Study Protocol C14011: MLN8237 A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated Rituximab and Vincristine; 2013; Sponsor: Millennium. UMASS direct funding: $290,000.00
40. DR12IMMU110. IM-T-hLL1-DOX-02: A Phase I/II Study of Immunotherapy with hLL1-DOX in Patients with Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia. Sponsor: Immunomedics; 2013; UMASS direct funding: $645,228.00
41. DR13NOVAR-BKM120. CBMK120Z2402. An open-label phase II study of BKM120 in patients with relapsed and refractory diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma; 2013; Sponsor: Novartis. UMASS direct funding: $320,945.00
42. CALGB 50604 A Phase II Trial of Response Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma. Opened at UMASS (2012-2016).
43. Drug C16017: An Open-label, Multicenter, Phase 2 Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma. Sponsor: Millennium; 2015 Tufts funding: $160,878
44. Investigator-initiated, NU12H09. A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas; 2014 to 2016; Tufts funding: $249,260 (*senior co-PI*)
45. S1106, CO13SWOG-S1106. A Randomized Phase II Trial of R-HCVAD/MTX/ARAC Induction followed by Consolidation with an Autologous Stem Cell Transplant vs. RBendamustine Induction for Patients ≤65 years of age with previously untreated Mantle Cell Lymphoma. Opened at UMASS (2013-2017).
46. Drug Affimed: A pharmacodynamically guided, dose-escalation, phase I study to assess the safety of AFM11 (recombinant antibody construct against human CD19 and CD3) in patients with relapsed and/or refractory CD19 positive B-cell NHL and adult B-precursor ALL; 2016 to 2017; Tufts funding: $621,864.
47. E2408, NCI; A 3-Arm Randomized Phase II Trial of Rituximab/Bendamustine (BR) Followed by Rituximab vs Bortezomib (Velcade®)-BR (BVR) Followed by Rituximab vs. BR Followed by Lenalidomide (Revlimid®)/Rituximab in High Risk Follicular Lymphoma. (ECOG- National PI). Sponsor: NCI/CTEP (ECOG biomarker/correlative studies budget: $1,329,702.00); 2008-2016
48. ECOG 1411 Intergroup Randomized Phase II Four Arm Study In Patients . 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab+ Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR). Opened at Tufts (2013-2017).
49. Investigator-initiated, NU14H09. A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients with MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen; total study funding: $755,440, CINJ funding: $255,100; 2018 to 2019; sponsor: Northwestern University/Takeda (PI)
50. Investigator-initiated, NU17H02; Phase II study of PET-directed frontline therapy with pembrolizumab and AVD for patients with classical Hodgkin lymphoma; Total study funding: $990,230, CINJ funding: $382,750; 2018 to 2020; sponsor: Northwestern University/Merck (PI)
51. E1412 Randomized Phase II Study of Lenalidomide R-CHOP (R2CHOP) v CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma. Opened at Tufts (2014-2017).
52. E4412 A Phase I Study With an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma. Opened at Tufts 2014-2017.
53. Industry: A Phase 1 Open-Label Study to Evaluate the Safety and Antitumor Activity of Loncastuximab Tesirine and Durvalumab in Patients with Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular; ADCT Therapeutics; CINJ funding: $522,520; 2018 to 2020; sponsor: (PI)
54. Investigator initiated: A Phase I/II Study of Ixazomib and Romidepsin in Relapsed/ Refractory Peripheral T-cell Lymphoma (PTCL); CINJ funding: $200,510; 2018 to 2021; sponsor: Big 10 Cancer Consortium (PI)
55. A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Older Patients or Patients with Significant Comorbidities Ineligible for Standard Chemotherapy. CINJ PI; November 2020 to current; NCT01716806. CINJ funding: $210,445
56. SWOG-S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma; July 2020 to current, CINJ PI; NCT03907488; CINJ funding: $147,309.44
57. Phase IB dose de-escalation study of the PI3k alpha/delta inhibitor, Copanlisib given in combination with the immunotherapeutic agents, Nivolumab and Rituximab in patients with relapsed/refractory indolent lymphoma. Big Ten Cancer Research Consortium BTCRC-LYM17-145. CINJ funding: $290,445
58. A Phase 2 Open-Label Study of Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Older Patients or Patients with Significant Comorbidities Ineligible for Standard Chemotherapy. CINJ funding: $367,970.88
* ***Investigator-initiated and Cooperative Group (correlative) combined clinical trial budgets, as study PI (2004-CURRENT): $5,402,857.76***
* ***Industry clinical trial combined budgets, as study PI (2004-CURRENT): $7,030,499.68***

**B. Co-Investigator** ***(bolded italics: active/ongoing)***

1. 1R01CA133063-01A1; NIH; Title: Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD; 7/14/2008 - 12/31/2010; annual direct costs: $19,455.
2. 1U01CA142555-01; NIH/NCI; Title: *Computerized Quantitative Imaging Assessment of Tumor Burden;* 04/01/2010 – 03/30/2016; annual direct costs: $18,336.
3. U01CA18097501; NIH/NCI; Title: *EMR Adverse Drug Event Detection for Pharmacovigilance;* 09/01/2014-08/31/16; Annual DC: $66,627
4. U01CA187947-01A1; *NIH/NCI; Computing, Optimizing, and Evaluating Quantitative Cancer Imaging Biomarkers; 09/01/2015 – 08/31/2020; direct costs: $103,136*
5. **R01 GM127714; NIH/NCI (Konry/Northeastern); *Title: An integrated acoustofluidic droplet sorting platform for dynamic monitoring of cell-cell interactions and functional phenotyping at single cell level; Role: co-investigator; 8/01/2018-7/31/2022;* *total direct costs:* $*905,388.***
6. **R01 EB012521; *NIH (Parekkadan/Rutgers); Title: Artificial, Humanized Stem Cell Niches; Role: co-investigator; 09/01/2018 – 08/31/2022; total direct costs: $1,176,504.***
7. **ORIEN NOVA Team Science Award; *Prime site Emory University (C.Flowers) with collaboration with Rutgers CINJ; “Classification of poor-risk relapsed Non Hodgkin Lymphoma subtypes”; 06/01/2019 to 05/31/2022; total direct costs: $1,000,000.***

**C. Pending**

1. R01 CA261752-01 (Zebrack/UMich), 07/01/2021-05/31/2026

*Social genomic mechanisms of health disparities among Adolescent and Young Adult (AYA) cancer survivors*

Role: Co-investigator

(NOTE: score of 20 at the 6th percentile; just in time completed for start date of July 1, 2021)

1. NIH R01 (Parsons/Tufts), 12/01/2021-11/30/2026; $320,155 DC (Rutgers Only)

*Modeling Multi-Source Data in Hodgkin Lymphoma (1 R01 CA262265-01)*

Role: Multi-PI

(NOTE: score of 35 atthe 16th percentile on A1 [funding at 12th percentile]; resubmission July 2021)

1. NIH R01 (Choi/Northwestern), 09/01/2021-08/31/2026, $89,035 DC (Rutgers Only) *Mechanisms of Lymphomagenesis for Skin-Resident Gamma Delta T Cells*

Role: Co-investigator

(NOTE: score of 39 at the 20th percentile on A1; resubmitted March 2021)

1. R01 (Konry/Northeastern); 06/01/2021-05/31/2024; $350,909 DC (Rutgers Only)

*Biologic interactions with anticancer therapeutics in novel lymphoma organoids using biomimetic tissue chip integrated microfluidics technology (R33 CA261700-01)*

Role: Multi-PI

(NOTE: score of 36 at the 15th percentile on A1; resubmission July 2021)

**PUBLICATIONS:**

A. Refereed Original Article in Journal (see Section D below for review papers, etc)

1. **Evens AM,** Kwaan HC, Kaufman D, Bennett CLet al. TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient following clopidogrel treatment: evidence of a non-immunological etiology. *Transplantation.* 2002; 27:885-887. PMID: 12364873

1. Shi B, Hsu HL, **Evens AM,** Gordon LI, and Gartenhaus RB. **Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies**. *Blood.* 2003; 102:297-302. PMID: 12637315
2. **Evens AM,** Prachand S, Shi B, Paniaqua M, Gordon LI, Gartenhaus R. Imexon-induced cytotoxicity in sensitive and resistant multiple myeloma cells: redox-independent apoptosis is mediated through caspase-8 dependent mechanisms. *Clinical Cancer Research.* 2004; 10:1481-1491. PMID: 14977852
3. Bennett CL, Luminari S, Nissenson A, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio T, Raisch DW, **Evens AM,** Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. *New England Journal of Medicine.* 2004; 30; 351:1403-8. PMID: 15459301
4. **Evens AM,** Lecane P, Magda D, Prachand S, Singhal S, Nelson J, Miller RA, Gartenhaus RB, Gordon LI. Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells. *Blood.* 2005; 105:1265-73. PMID: 15388578
5. Gidron A, Verma A, Doyle M, Boggio L, **Evens AM,** Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J. Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies? *Bone Marrow Transplant.* 2005; 35:243-6. PMID: 15580281
6. Carson KR, **Evens AM,** Bennett CL, Luminari S. Clinical characteristics of erythropoietin-associated pure red cell aplasia. *Best Pract Res Clin Haematol.* 2005; 18:467-472. PMID: 15792921
7. **Evens AM,** Bennett CL, Luminari S. Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. *Best Pract Res Clin Haematol.* 2005; 18:481-489. PMID: 15792923
8. Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM, Carson KR, Belknap SM, Trifilio SM, Schumock GT, Yarnold PR, Davidson CJ, **Evens AM,** Kuzel TM, Parada JP, Cournoyer D, West DP, Sartor O, Tallman MS, Raisch DW. The Research on Adverse Drug Events and Reports (RADAR) project. *JAMA.* 2005; 293:2131-40. PMID: 15870417
9. [Tomblyn M](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Tomblyn+M%22%5BAuthor%5D), [Gordon LI](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Gordon+LI%22%5BAuthor%5D), [Singhal S](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Singhal+S%22%5BAuthor%5D), [Tallman MS](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Tallman+MS%22%5BAuthor%5D), [Williams S](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Williams+S%22%5BAuthor%5D), [Winter JN](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Winter+JN%22%5BAuthor%5D), [**Evens A**](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Evens+A%22%5BAuthor%5D)**M,** [Mehta J](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Mehta+J%22%5BAuthor%5D). Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF. *Bone Marrow Transplant.* 2005; 36:663-6. PMID: 16062175
10. [Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, **Evens AM,** Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B, Sharma R, Costello S, Toffelmire EB, Wells GA, Messner HA, Yarnold PR, Trifilio SM, Raisch DW, Kuzel TM, Nissenson A, Lim LC, Tallman MS, Casadevall N.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16099877&query_hl=1) Long-term outcome of individuals with pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant epoetin: A follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. *Blood.* 2005 Nov 15;106(10):3343-7. PMID: 16099877
11. Singhal S, Gordon LI, Tallman MS, Winter JN, **Evens AM,** Frankfurt O, Williams SF, Grinblatt D, Kaminer L, Meagher R, Mehta J. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2006; 37:553-7. PMID: 16444282
12. [Trifilio S, Gordon L, Singhal S, Tallman M, **Evens A,** Rashid K, Fishman M, Masino K, Pi J, Mehta J.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16708061&query_hl=5&itool=pubmed_docsum) Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. *Bone Marrow Transplant.* 2006; 37:997-1001. PMID: 16708061
13. [McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, **Evens AM,** Kuzel TM, Trifilio SM, Raisch DW, Kell J, Deangelo DJ, Giles FJ.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16959316&query_hl=1&itool=pubmed_docsum) Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project. *Leukemia Research.* 2007; 31:599-604. PMID: 16959316
14. Mehta J, Gordon LI, Tallman MS, Winter JN, **Evens AM,** Frankfurt O, Williams SF, Grinblatt D, Kaminer L, Meagher R, Singhal S. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? *Bone Marrow Transplant*. 2006; 38:95-100. PMID: 16751789
15. [Bennett CL, **Evens AM,** Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17054431&query_hl=1&itool=pubmed_docsum) Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. *British Journal of Haematology.* 2006; 135:642-50. PMID: 17054431
16. [Bennett CL, Angelotta C, Yarnold PR, **Evens AM,** Zonder JA, Raisch DW, Richardson P.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17148721&query_hl=1&itool=pubmed_docsum)Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. *JAMA.* 2006; 296:2558-60. PMID: 17148721
17. [Chen YH, Peterson LC, Dittmann D, **Evens A,** Rosen S, Khoong A, Shankey TV, Forman M, Gupta R, Goolsby CL.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17210531&query_hl=1&itool=pubmed_docsum)Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to lgVH mutational status in chronic lymphocytic leukemia. *Am J Clin Pathol.* 2007; 127:182-91. PMID: 17210531
18. **Evens AM,** Altman JK, Mittal BB, Hou N, Rademaker A, Patton D, Kaminer L, Williams S, Duffey S, Variakojis D, Singhal S, Tallman MS, Mehta J, Winter JN, Gordon LI.); Phase I/II Trial of Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. *Annals of Oncology* 2007; 18:679-88. PMID: 17307757
19. [Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, Chamilos G, Palella F, Kennedy L, Mullane K, Tallman MS, **Evens A,** Scheetz MH, Blum W, Kontoyiannis DP.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17310132&query_hl=26&itool=pubmed_docsum) Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. *Bone Marrow Transplant.* 2007; 39:425-9. PMID: 17310132
20. [Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, Singhal S, Williams S, Winter J, Tallman M, Gordon L, Frankfurt O, **Evens A,** Mehta J.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17351937&query_hl=26&itool=pubmed_docsum) Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. *Cancer.* 2007; 109:1532-5. PMID: 17351937
21. **Evens AM,** Cilley J, Ortiz T, Gounder M, Hou N, Rademaker A, Miyata S, Catsaros K, Augustyniak C, Bennett CL, Tallman MS, Variakojis D, Winter JN, Gordon LI. G-CSF is Not Necessary to Maintain Over 99% Dose-Intensity With ABVD in the Treatment of Hodgkin Lymphoma: Low Toxicity and Excellent Outcomes in a 10-year Analysis. *British Journal of Haematology.* 2007; 137:545-52. PMID: 17459049
22. [Chiu BC, Soni L, Gapstur SM, Fought AJ, **Evens AM,** Weisenburger DD.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17484069&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Obesity and risk of non-Hodgkin lymphoma (United States). *Cancer Causes Control.* 2007; 18:677-85. PMID: 17484069
23. [**Evens AM,** Ziegler SL, Gupta R, Augustyniak C, Gordon LI, Mehta J.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17875237&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. *Clin Lymphoma Myeloma.* 2007; 7:472-4. PMID: 17875237
24. [Bennett CL, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM, Edwards BJ, Hurdle JF, West DP, Lau DT, Angelotta C, Weitzman SA, Belknap SM, Djulbegovic B, Tallman MS, Kuzel TM, Benson AB, **Evens A,** Trifilio SM, Courtney DM, Raisch DW.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17533207&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. *Archives of Internal Medicine;* 2007; 167:1041-9. PMID: 17533207
25. [Tigue CC, McKoy JM, **Evens AM,** Trifilio SM, Tallman MS, Bennett CL.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17563736&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. *Bone Marrow Transplant.* 2007; 40:185-92. PMID: 17563736

1. [Soni LK, Hou L, Gapstur SM,](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17686627&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) **[Evens AM,](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17686627&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum)** [Weisenburger DD, Chiu BC.](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17686627&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum) Sun exposure and non-Hodgkin lymphoma: A population-based, case-control study. *European Journal of Cancer*. 2007; 43:2388-95. PMID: 17686627
2. **Evens AM,** Winter JN, Hou N, Nelson BP, Rademaker A, Patton D, Singhal S, Frankfurt O, Tallman MS, Rosen ST, Mehta J, Gordon LI. A Phase II Clinical Trial of Intensive Chemotherapy Followed by Consolidative Stem Cell Transplant: Long-Term Follow-up in Newly Diagnosed Mantle Cell Lymphoma. *British Journal of Haematology;* 2008; 140:385-93. PMID: 18162124
3. Chiu BC, Dave BJ, Ward MH, Fought AJ, Hou L, Jain S, Gapstur S, **Evens AM,** Zahm SH, Blair A, Weisenburger DD. Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma. *Cancer Causes Control.* 2008; 19:859-67. PMID: 18386141
4. **Evens AM,** Schumacker PT, Helenowski IB, Singh A, Dokic D, Keswani A, Kordeluk E, Raji A, Winter JN, Jovanovic BD, Holmgren A, Nelson BP, Gordon. LI. Hypoxia-Inducible Factor-Alpha (HIF-) Activation in Non-Hodgkins Lymphoma (NHL): Relationship to the Thioredoxin Family. *British Journal of Haematology;* 2008, 141:676-80. PMID: 18422776
5. Kelemen K, Peterson LC, Helenowski I, Goolsby CL, Jovanovic B, Miyata S, Arana O, Rosen ST, Winter JN, Nelson BP, Gordon LI, **Evens AM.** CD23-Positive Mantle Cell Lymphoma: A Clinical Pathologic Entity Associated with Superior Outcome Compared to CD23-Negative Disease. *American Journal of Clinical Pathology;* 2008; 130:166-77. PMID: 18628084
6. Lankes HA, Fought AJ, **Evens AM,** Weisenburger DD, Chiu BC. [Vaccination history and risk of non-hodgkin lymphoma: a population-based, case-control study.](http://www.ncbi.nlm.nih.gov/pubmed/19011978?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) *Cancer Causes Control.* 2009; 20:517-23. PMID: 19011978
7. Singh V, Krishnamurthy J, Duffey S, Meagher R, Villa M, Monreal J, **Evens A,** Frankfurt O, Altman J, Gordon L, Tallman M, Williams S, Winter J, Singhal S, Mehta J.[Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?](http://www.ncbi.nlm.nih.gov/pubmed/18836491?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) *Bone Marrow Transplant.* 2009; 43:301-5. PMID: 18836491
8. Winter JN, Inwards DJ, Spies S, Rademaker AW, Weitner BB, Williams SF, Tallman MS, Micallef I, Mehta J, Singhal S, **Evens AM,** Zimmer M, Molina A, White CA, Gordon LI. Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma. *Journal of Clinical Oncology.* 2009; 113:4834-40. PMID: 19255322
9. Carson KR, **Evens AM,** Richey EA, Habermann TH, Focosi D, Seymour JF, Laubach J, Bawn S, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz ad, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major E, and Bennett CL. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: A report of 56 cases from the Research on Adverse Drug Event and Reports (RADAR) project. *Blood.* 2009; 113:4834-40. PMID: 19264918
10. Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, **Evens AM**.PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. *Clinical Cancer Research.* 2009; 15:3354-65. PMID: 19417023
11. Mehta J, Frankfurt O, Altman J, **Evens A,** Tallman M, Gordon L, Williams S, Winter J, Krishnamurthy J, Duffey S, Singh V, Meagher R, Grinblatt D, Kaminer L, Singhal S. [Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation.](http://www.ncbi.nlm.nih.gov/pubmed/19603344?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) *Leukemia and Lymphoma.* 2009; 14:1-8. PMID: 19603344
12. **Evens AM,** Spies WG, Helenowski IB, Patton D, Spies S, Jovanovic BD, Miyata S, Hamilton E, Variakojis D, Chen J, Naumovski L, Rosen ST, Winter JN, Miller RA, Gordon LI. The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y] Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial. *Clinical Cancer Research.* 2009; 15:6462-71. PMID: 19825958
13. **Evens AM,** Sehn LH, Farinha P, Nelson BP, Raji A, Lu Y, Brakman A, Parimi V, Winter JN, Schumacker PT, Gascoyne RD, Gordon LI. Hypoxia-Inducible Factor-1 Alpha (HIF-1α) Expression Predicts Superior Survival in Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP. *Journal of Clinical Oncology.* 2010; 28:1017-24. PMID: 20048181
14. O'Connor OA, Portlock C, Moskowitz C, Hamlin P, Straus D, Gerecitano J, Gonen M, Dumitrescu O, Sarasohn D, Butos J, Neylon E, Mac-Gregor Cortelli B, Blumel S, **Evens AM,** Zelenetz AD, Wright J, Cooper B, Winter J, Vose J. Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. *Clinical Cancer Research.* 2010; 16:719-26. PMID: 20068103
15. **Evens AM,** David KA, Helenowski IB, Nelson B, Kaufman D, Kircher S, Gimelfarb, Hattersley E, Mauro L, Jovanovic B, Chadburn AM, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory SA, Gordon LI, Shammo JM, Smith S, Smith SM. Multicenter Analysis of 80 Solid Organ Transplant Recipients with Posttransplantation Lymphoproliferative Disease (PTLD): Outcomes and Prognostic Factors in the Modern Era. *Journal of Clinical Oncology.* 2010; 28:1038-46. PMID: 20085936
16. Bhalla S, Gordon LI, David K, Prachand S, Singh AT, Yang S, Winter JN, Guo D, O'Halloran T, Platanias LC, **Evens AM.** [Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms.](http://www.ncbi.nlm.nih.gov/pubmed/20408844) *British Journal of Haematology.* 2010; 150:365-9. PMID: 20408844
17. Singh AT, **Evens AM,** Anderson RJ, Beckstead JA, Sankar N, Sassano A, Bhalla S, Yang S, Platanias LC, Forte TM, Ryan RO, Gordon LI. [All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma.](http://www.ncbi.nlm.nih.gov/pubmed/20507312) *British Journal of Haematology.* 2010; 158-169. PMID: 20507312
18. Singh AT, **Evens AM**, Prachand SN, Gordon LI. Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines. *Anticancer Res.* 2010; 30:1131-6. PMID: 20530418
19. Li SC, Chen YC, **Evens AM,** Lee CC, Liao HF, Yu CC, Tung YT, Su YC. [Rituximab-induced late onset neutropenia in newly-diagnosed B-cell lymphoma correlates with Fc receptor FcgammaRIIIa 158(V/F) polymorphism.](http://www.ncbi.nlm.nih.gov/pubmed/20730791) *Am J Hematol.* 2010; 85:810-2. PMID: 20730791
20. Yang S, **Evens AM,** Prachand S, Singh ATK, Bhalla S,David K, Gordon LI. Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone Andrographolide, the active component of Andrographis paniculata. *Clinical Cancer Research.* 2010; 16:4755-68. PMID: 20798229
21. Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, Choi WW, Au WY, Srivastava G, Czader MB, Rizzieri DA, Lagoo AS, Lugar PL, Mann KP, Flowers CR, Bernal-Mizrachi L, Naresh KN, **Evens AM,** Gordon LI, Luftig M, Friedman DR, Weinberg JB, Thompson MA, Gill JI, Liu Q, How T, Grubor V, Gao Y, Patel A, Wu H, Zhu J, Blobe GC, Lipsky PE, Chadburn A, Dave SS. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. *Blood.* 2010; 116:e118-27. PMID: 20733160
22. **Evens AM,** Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap S, Dai MS, Chiu BCH, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY. Rituximab­-associated hepatitis B virus (HBV) reactivation in lymphooproliferative diseases: meta-analysis and examination of FDA safety reports. *Annals of Oncology.* 2011. 22:1170-80. PMID: 21115603
23. Bhalla S, **\*Evens AM,** Dai B, Prachand S, Gordon LI, Gartenhaus RB. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. *Blood.* 2011; 22:1183-95. **(AME and SB contributed equally to the manuscript)** PMID: 21628402
24. Chiu BC, Kwon S, **Evens AM,** Surawicz T, Smith SM, Weisenburger DD. [Dietary intake of fruit and vegetables and risk of non-Hodgkin lymphoma.](http://www.ncbi.nlm.nih.gov/pubmed/21695384) *Cancer Causes Control.* 2011; 118:1052-61.PMID: 21695384
25. Goddard A, Borovicka JH, West DP, **Evens AM,** Laumann A. Diffuse large B-cell lymphoma associated with the use of biologic and other investigational agents: the importance of long-term post-marketing safety surveillance. *J Drugs Dermatol.* 2011; 10:80-3. PMID: 21197528
26. Chen YH, Chadburn A, **Evens AM**, Winter JN, Gordon LI, Chenn A, Goolsby C, Peterson L. Clinic[al, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8-γδ T-cell large granular lymphocytic leukemia.](http://www.ncbi.nlm.nih.gov/pubmed/21757603) *American Journal of Clinical Pathology.* 2011; 136:289-99. PMID: 21757603
27. Nabhan C, Smith SM, Helenowski I, RamsdaleE, Parsons B, Karmali R, Feliciano J, Hanson B, Smith S, McKoy J, Larsen A, Hantel A, Gregory SA, **Evens AM.** Analysis of Very Elderly (≥ 80 Years) Non-Hodgkin Lymphoma: Impact of Functional Status and Co-morbidities on Outcome. *British Journal of Haematology.* 2012; 156:196-204. PMID: 22084970
28. **Evens AM**, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, Parsons B, Smith S, Larsen A, McKoy JM, Jovanovic B, Gregory S, Gordon LI, Smith SM. [A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.](http://www.ncbi.nlm.nih.gov/pubmed/22117038) *Blood.* 2012; 119:692-5. PMID: 22117038
29. Raizer JJ, Rademaker A, **Evens AM,** Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA. [Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.](http://www.ncbi.nlm.nih.gov/pubmed/22179954) *Cancer.* 2012; 118:3743-8. PMID: 22179954
30. **Evens AM,** Antillón M, Aschebrook-Kilfoy B, Chiu BC. [Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis.](http://www.ncbi.nlm.nih.gov/pubmed/22241896) *Annals of Oncology* 2012; 23:2128-37. PMID: 22241896
31. Nelson BP, Wolniak KL, **Evens AM**, Chenn A, Maddalozzo J, Proytcheva M. Early Posttransplant Lymphoproliferative Disease: Clinicopathologic Features and Correlation With mTOR Signaling Pathway Activation. *American Journal of Clinical Pathology.* 2012; 138:568-578. PMID: 23010712
32. Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, **Evens AM**, Benjamin RS. [An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.](http://www.ncbi.nlm.nih.gov/pubmed/22910841)  *Annals of Oncology.* 2013; 24:257-63. PMID: 22910841
33. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, **Evens AM,** Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations in Burkitt lymphoma. *Nature Genetics.* 2012; 44:1321-5. PMID: 23143597
34. Cerny J, Yu H, Ramanathan M, Raffel GD, Walsh WV, Fortier N, Shanahan L, O'Rourke E, Bednarik J, Barton B, Kroll-Desrosiers A, Hao S, Woda B, Hutchinson L, **Evens AM,** Rosmarin AG, Nath R. Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). *British Journal of Haematology.* 2013; 160:262-6. PMID: 23116454
35. Roy R, **Evens AM,** Patton D, Gallot L, Larson A, Rademaker A, Cilley J, Spies S, Variakojis D, Gordon LI, Winter JN. Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. *Leukemia & Lymphoma.* 2013; 54:497-502. PMID: 22906230
36. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, **Evens AM,** Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS. Genetic heterogeneity of diffuse large B-cell lymphoma. *Proc Natl Acad Sci U S A.* 2013; 110:1398-403. PMID: 23292937
37. **Evens AM,** Hong F, Gordon LI, Fisher RI, Bartlett N, Connors JM, Wagner H, MK Gospodarowicz, Cheson BC, Stiff PJ, Advani R, Miller TP, Kahl BS, Hoppe RT, Horning SJ. The Efficacy and Tolerability of ABVD and Stanford V in Older Hodgkin Lymphoma Patients: A Comprehensive Analysis from the North American Intergroup Trial E2496. *British Journal of Haematology*. 2013; 161:76-86. PMID: 23356491
38. **Evens AM,** Choquet S, Kroll-Desrosiers AR, Jagadeesh D, Smith SM, Morschhauser F, LeblondV, Roy R, Barton B, Gordon LI, Gandhi MK,  [Dierickx](http://jco.ascopubs.org/search?author1=Daan+Dierickx&sortspec=date&submit=Submit) D, Schiff D, Habermann TM, Trappe R. Primary CNS Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era. *American Journal of Transplantation*. 2013; 13:1512-22. PMID: 23721553
39. Ollberding NJ, **Evens AM,** Aschebrook-Kilfoy B, Caces DB, MD, Weisenburger DD, MD, Smith SM, Chiu BC-H. Cigarette Smoking and Overall Survival in Patients with Non-Hodgkin Lymphoma: A Pooled Analysis of Prospective Studies. *British Journal of Haematology.* 2013; 163:352-6; PMID: 23909494
40. **Evens AM,** Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg JW. Stem Cell Transplantation for Follicular Lymphoma Relapsed/Refractory After Prior Rituximab: A Comprehensive Analysis from the NCCN Lymphoma Outcomes Project. *Cancer*. 2013; 119:3662-71; PMID: 23921646
41. **Evens AM,** Rosen ST, Helenowski I, Kline J, Larsen A, Colvin J, Winter JN, Van Besien KM, Gordon LI, Smith SM. A Phase I/II Trial of Bortezomib Combined Concurrently with Gemcitabine for Relapsed or Refractory DLBCL and Peripheral T-cell Lymphomas. *British Journal of Haematology.* 2013; 163:55-61; PMID: 23927371
42. **Evens AM,** Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Dagan LN, Abdallah R, Kroll A, Yarber JL, **Sandoval J,** Parker LM, Gordon LI, Blum KA, Flowers C, Leonard JP, Habermann TM, Bartlett NL. Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis. *Journal of Clinical Oncology,* 2013; 31:4132-9.PMID: 24043736
43. **Evens AM,**Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI.A Multicenter Phase 2 Study Incorporating High-Dose Rituximab and Liposomal Doxorubicin into the CODOX-M/IVAC Regimen for Untreated Burkitt Lymphoma. *Annals of Oncology.* 2013; 24:3076-81. PMID: 24146219
44. Bhalla S, **Evens AM,** Prachand S, Schumacker PT, Gordon LI. [Paradoxical Regulation of Hypoxia Inducible Factor-1α (HIF-1α) by Histone Deacetylase Inhibitor in Diffuse Large B-Cell Lymphoma.](http://www.ncbi.nlm.nih.gov/pubmed/24312289) *PLoS One.* 2013; 8:e81333; PMID: 24312289
45. Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, Bast M, Advani RH, Tibshirani R, **Evens AM,** Islam N, Leonard JP, Martin P, Zelenetz AD, Lossos IS. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. *British Journal of Haematology.* 2014; 165:358-63. PMID: 24467658
46. Nabhan C, Aschebrook-Kilfoy B, Chiu BC, Smith SM, Shanafelt TD, **Evens AM,** Kay NE. The Impact of Race, Ethnicity, Age, and Sex on Clinical Outcome in Chronic Lymphocytic Leukemia: A Comprehensive SEER Analysis in the Modern Era. *Leukemia and Lymphoma.* 2014; 55:2778-84; PMID: 24588735
47. Gentzler RD, **Evens AM,** Rademaker AW, Weitner BB, Mittal BB, Dillehay GL, Petrich AM, Altman JK, Frankfurt O, Variakojis D, Singhal S, Mehta J, Williams S, Kaminer L, Gordon LI, Winter JN. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. *British Journal of Haematology.* 2014; 165:793-800; PMID: 24628515
48. Nabhan C, Aschebrook-Kilfoy B, Chiu BC, Kruczek K, Smith SM, **Evens AM.** The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras. *American Journal of Hematology.* 2014; 89:633-8; PMID: 24633911
49. **Evens AM,** Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI. [Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-hodgkin lymphoma: a multicentre phase II study.](http://www.ncbi.nlm.nih.gov/pubmed/24761968) *British Journal Haematology.* 2014; 166(4):514-20; PMID: 24761968
50. Gandhi MD, **Evens AM,** Fenske TS, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio SM, Raisch DW, West DP, Gordon LI, Winter JN. [Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.](http://www.ncbi.nlm.nih.gov/pubmed/24786458) *Blood.* 2014; 123:2895-7. PMID: 24786458
51. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, **Evens AM**, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. *Blood.* 2014; 124:2354-61; PMID: 25161267
52. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, **Evens AM**. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. *Annals of Oncology.* 2014; 25:2211-7. PMID: 25193992
53. Ravi D, Bhalla S, Gartenhaus RB, Crombie J, Kandela I, Sharma J, Mazar A, **Evens AM**. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models. *Clinical Cancer Research.* 2014; 20:6023-33. PMID: 25316819
54. Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, **Evens AM**, Mustjoki S, Tallman MS. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). *Leukemia.* 2014; 29:886-94. PMID: 25306898
55. Trabucco SE, Gerstein RM, **Evens AM**, Bradner JE, Shultz LD, Greiner DL, Zhang H. Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma. *Clinical Cancer Research.* 2015; 21:113-22; PMID: 25009295
56. **Evens AM**, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA. Gray zone lymphoma with features intermediate between classical hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort. *American Journal of Hematology.* 2015 Jun 4. [Epub ahead of print] PMID: 26044261
57. Wage J, Ma L, Peluso M, Lamont C, **Evens AM,** Hahnfeldt P, Hlatky L, Beheshti A. Proton irradiation impacts age-driven modulations of cancer progression influenced by immune system transcriptome modifications from splenic tissue. *Journal of Radiation Research.* 2015; 56:792-803. PMID: 26253138
58. **Evens AM**, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL. A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. *Clinical Cancer Research.* 2015 Oct 19. [Epub ahead of print] PMID: 26482040.
59. Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, **Evens AM**, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, M Vose J. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. *British Journal of Haematology.* 2016 Feb; 172(4):535-44. PMID: 26627450
60. Lishner M, Avivi I, Apperley JF, Dierickx D, **Evens AM**, Fumagalli M, Nulman I, Oduncu FS, Peccatori FA, Robinson S, Van Calsteren K, Vandenbroucke T, Van den Heuvel F, Amant F. Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. *Journal of Clinical Oncology*. 2016 Feb 10;34(5):501-8. PMID: 26628463
61. Beheshti A, Neuberg D, McDonald JT, Vanderburg CR, **Evens AM**. The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks. *Cancer Informatics.* 2015; 14:141-8. PMID: 26691437
62. Rosenberg AS, Klein AK, Ruthazer R, **Evens AM**. Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival. *American Journal of Hematology.* 2016; 91(6):560-5. PMID:26928381
63. Perales MA, Ceberio I, Armand P, Burns LJ, Chen R, Cole PD, **Evens AM**, Laport GG, Moskowitz CH, Popat U, Reddy NM, Shea TC, Vose JM, Schriber J, Savani BN, Carpenter PA; American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant.* 2015; 21:971-83. PMID: 25773017
64. Ravi D, Beheshti A, Abermil N, Passero F, Sharma J, Coyle M, Kritharis A, Kandela I, Hlatky L, Sitkovsky MV, Mazar A, Gartenhaus RB, **Evens AM**. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma. *Cancer Research.* 2016; 76 (11):3319-31. PMID: 26988986
65. Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, **Evens AM**, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. *Journal of Clinical Oncology*. 2016 Jun 10;34(17):2020-7. PMID: 27069074
66. Linendoll N, Saunders T, Burns R, Nyce JD, Wendell KB, **Evens AM**, Parsons SK. Health-related quality of life in Hodgkin lymphoma: a systematic review. *Health Qual Life Outcomes.* 2016; 14(1):114. PMID: 27473596
67. Xing W, Dresser K, Zhang R, **Evens AM**, Yu H, Woda BA, Chen BJ. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications. *Oncotarget.* 2016; 7(37):59976-59986. PMID: 27527850
68. Rosenberg AS, Ruthazer R, Paulus JK, Kent DM, **Evens AM**, Klein AK. Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders. *Clin Lymphoma Myeloma Leuk.* 2016; 16(12):684-692.e3. PMID: 27771291
69. Diefenbach CS, Connors JM, Friedberg JW, Leonard JP, Kahl BS, Little RF, Baizer L, **Evens AM**, Hoppe RT, Kelly KM, Persky DO, Younes A, Kostakaglu L, Bartlett NL. Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. *J Natl Cancer Inst.* 2016 Dec 31;109(4). Peer-reviewed. PMID: 28040700
70. Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, **Evens AM**, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C. Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. Bi*ol Blood Marrow Transplant.* 2016; 22(9):1543-51. Peer-reviewed. PMID: 27131863
71. Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, **Evens AM**. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. *Blood.* 2016; 28(18):2199-2205. PMID: 27601462
72. Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, **Evens AM**, Cohen JB, Flowers CR, Fenske TS, Hamadani M. Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. *American Journal of Hematology.* 2017 Feb;92(2):161-170. PMID: 27880984
73. Beheshti A, Vanderburg C, McDonald JT, Ramkumar C, Kadungure T, Zhang H, Gartenhaus RB, **Evens AM**. A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma. *PLoS One.* 2017; 12(1):e0170521. PMID: 28107482
74. Bertrand KA, Shingala J, **Evens AM**, Birmann BM, Giovannucci E, Michaud DS. Periodontal disease and risk of non-Hodgkin lymphoma in the Health Professionals Follow-Up Study. *Int J Cancer.* 2017 Mar 1;140(5):1020-1026. PMID: 27861844
75. McKinney M, Moffitt AB, Gaulard P, Travert M, De Leval L, Nicolae A, Raffeld M, Jaffe ES, Pittaluga S, Xi L, Heavican T, Iqbal J, Belhadj K, Delfau-Larue MH, Fataccioli V, Czader MB, Lossos IS, Chapman-Fredricks JR, Richards KL, Fedoriw Y, Ondrejka SL, Hsi ED, Low L, Weisenburger D, Chan WC, Mehta-Shah N, Horwitz S, Bernal-Mizrachi L, Flowers CR, Beaven AW, Parihar M, Baseggio L, Parrens M, Moreau A, Sujobert P, Pilichowska M, **Evens AM**, Chadburn A, Au-Yeung RK, Srivastava G, Choi WW, Goodlad JR, Aurer I, Basic-Kinda S, Gascoyne RD, Davis NS, Li G, Zhang J, Rajagopalan D, Reddy A, Love C, Levy S, Zhuang Y, Datta J, Dunson DB, Davé SS. The Genetic Basis of Hepatosplenic T-cell Lymphoma. *Cancer Discovery.* 2017; 7:369-379. PMID: 28122867
76. Galanina N, Smith SM, Liao C, Petrich A, Libao B, Gartenhaus R, Westin JR, Cohen KS, Knost JA, Stadler WM, Doyle A, Karrison T, Gordon LI, **Evens AM.** University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. *Br J Haematol.* 2017 Apr 17. doi: 10.1111/bjh.14544. [Epub ahead of print] PMID: 28419407
77. Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, **Evens AM,** Flowers CR, Cohen JB, Fenske TS, Hamadani M, Costa LJ. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy. *Cancer.* 2017 Jul 27.  [Epub ahead of print] PMID: 28749548
78. Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, **Evens AM**, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. *Cell.* 2017. 171:481-494; PMID: 2812286.
79. Fu J, Upshaw J, Cohen J, Rodday AM, Saunders T, Kelly M, **Evens AM**, Parsons SK. Assessing the risk of cardiac toxicity after contemporary treatment for Hodgkin lymphoma: a systematic review. *Leuk Lymphoma*. 2017; 1-5.  PMID: 29214876
80. Pilichowska M, Pittaluga, S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LS, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KS, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, **Evens AM.** Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. *Blood Advances,* 2017; 1(26):2600-2609. PMID: 29296913
81. Sarkar S, Sabhachandani P, Ravi D, Potdar S, Purvey S, Beheshti A, **Evens AM**, Konry T. Dynamic Analysis of Human Natural Killer Cell Response at Single-Cell Resolution in B-Cell Non-Hodgkin Lymphoma. *Frontiers in Immunology*. 2017; 8:1736. PMID: 29312292
82. Henderson TO, Parsons SK, Wroblewski K, Chen L, Hong F, Smith SM, McNeer J, Advani R, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard J, Kahl BS, Kelly K, Schwartz CL15, Li H, Friedberg JW, Friedman DL, Gordon LI, **Evens AM.**Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children’s Oncology Group (COG AHOD 0031) Comparative Analysis. *Cancer.* 2018; 124(1):136-144. PMID: 28902390
83. Bhalla K, Jaber S, Nahid M N, Underwood K, Beheshti A, Landon A, Bhandary B, Bastian P, **Evens AM**, Haley J, Polster B, Gartenhaus RB. Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL. *Science Reports*. 2018 Jan 15;8(1):744. PMID: 29335581
84. Kapadia B, Nanaji NM, Bhalla K, Bhandary B, Lapidus R, Beheshti A, **Evens AM**, Gartenhaus RB. Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL. *Nature Communications.* 2018; 9:829.  PMID: 29483509
85. McDonald JT, Kritharis A, Beheshti A, Pilichowska M, Burgess K, Ricks-Santi L, McNiel E, London CB, Ravi D, **Evens AM**. Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. *Oncotarget.* 2018; 9:22693-22702. PMID: 29854308
86. Parsons SK, Kelly MJ, Cohen JT, Castellino SM, Henderson TO, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, **Evens AM**. Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. *British Journal of Haematology.* 2018; 182:212-221; PMID: 29707774
87. **Evens AM**, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA. [Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.](https://www.ncbi.nlm.nih.gov/pubmed/30179569) *Journal of Clinical Oncology*. 2018; 30:3015-3022; PMID: 30179569.
88. [Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.](https://www.ncbi.nlm.nih.gov/pubmed/30277110) Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Glenn MJ, Hernandez-Ilizaliturri FJ, Flowers CR, **Evens AM**, Zhou Z, Lansigan F, Barta SK, Cohen JB, Fenske TS, Costa LJ. *Leukemia and Lymphoma*. 2019; 60:940-946; PMID 30277110
89. [Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.](https://www.ncbi.nlm.nih.gov/pubmed/30277102) Sharman JP, Forero-Torres A, Costa LJ, Flinn IW, Inhorn L, Kelly K, Bessudo A, Fayad LE, Kaminski MS, **Evens AM**, Flowers CR, Sahin D, Mundt KE, Sandmann T, Fingerle-Rowson G, Vignal C, Mobasher M, Zelenetz AD. *Leukemia and Lymphoma*. 2019; 60:894-903; PMID: 30277102
90. Sabhachandani P, Sarkar S, Mckenney S, Ravi D, **Evens AM,** Konry T. Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release. *J Control Release.* 2018; 295:21-30; PMID: 30550941
91. Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, **Evens AM,** Kahl BS. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma*. British Journal of Haematology.* 2018; 184:524-535; PMID: 30575016.
92. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, **Evens AM**, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. *Journal of Clinical Oncology.* 2019; 37:471-480. PMID: 30615550
93. Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, **Evens AM**, Scott DW, Rimsza LM, Friedberg JW. Serum levels of TARC, MDC, IL10 and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. *Blood.* 2019; 133:1762-1765. PMID: 30723079.
94. Paudel N, Schulze D, Gentzler RD, **Evens AM,** Helenowski I, Dillehay G, Frankfurt O, Mehta J, Donnelly ED, Gordon LI, Winter JN, Mittal BB. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma. *Int J Radiat Oncol Biol Phys.* 2019 Feb 11. PMID: 30763660
95. Chen BJ, Dashnamoorthy R, Galera P, Makarenko V, Chang H, Ghosh S, **Evens AM.** The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. *Oncotarget.* 2019 Mar 12;10(21):2030-2040. PMID: 31007846
96. Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, Leblanc M, Rimsza LM, Bartlett NL, **Evens AM**, LaCasce AS, Barr PM, Knopp MV, Hsi E, Leonard JP, Kahl B, Smith SM, Friedberg JW. Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma. *Blood.* 2019; 134:1238-1246. PMID: 31331918
97. Passero FC Jr, Ravi D, McDonald JT, Beheshti A, David KA, **Evens AM**. Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma.*British Journal of Haematology.* 2019 Aug 26. doi: 10.1111/bjh.16160. [Epub ahead of print]
98. Beheshti A, Stevenson K, Vanderburg C, Ravi D, McDonald JT, Christie AL, Shigemori K, Jester H, Weinstock DM, **Evens AM.** Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models. *Science Reports.* 2019 Nov 20; 9(1):17161. PMID: 31748664
99. Ravi D, Sarkar S, Purvey S, Passero F, Beheshti A, Chen Y, Mokhtar M, David K, Konry T, **Evens AM.** Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma*. Leukemia.* 2020; 34:1291-1304.  PMID: 31772298
100. Rodday AM, Hahn T, Kumar AJ, Lindenauer PK, Friedberg JW, **Evens AM**, Parsons SK. First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study. *Br J Haematol.* 2020; 190:222-235. PMID: 32102579
101. Allen PB, Ayers A, Behera M, **Evens AM**, Flowers C. A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma. *Leuk Lymphoma.* 2020; 26:1-10; PMID: 32090325
102. Ha CS, LeBlanc M, Schöder H, Pinnix CC, Bartlett NL,**Evens AM**, Hsi ED, Rimsza L, Knopp MV, Zhang J, Leonard JP, Kahl BS, Li H, Smith S, Constine LS, Friedberg JW. Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Analysis of SWOG S0816. *Leuk Lymphoma*. 2020; 26;1-6. PMID: 32452714
103. **Evens AM**, Hong F, Habermann TM, Advani RH, Gascoyne RD, Witzig TE, Quon A, Ranheim EA, Ansell SM, Cheema PS, Dy PA, O'Brien TE, Winter JN, Cescon TP, Chang JE, Kahl B. A 3-Arm Randomized Phase II Study of Bendamustine/Rituximab With Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. *Clinical Cancer Research*; 2020; 26:4468-4477. PMID: 32532790
104. **Evens AM**, Danilov AV, Jagadeesh D, Sperling AL, Kim SH, Vaca RA, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond D, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Sarraf Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach CS, Straker-Edwards A, Klein A, Blum K, Boughan K, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre V, Zayac AS, Ramdial J, Maliske S, Epperla N, Venugopal P, Feldman T, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning M, Caimi PF, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP. Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers. *Blood.* 2021; 137:374-386. PMID: 32663292
105. Allen PB, Savas H, **Evens AM,** Advani R, Palmer B, Pro B, Karmali R, Mou E, Bearden J, Dillehay G, Bayer R, Eisner RM, Chmiel JS, O'Shea KL, Gordon LI, Winter JN. Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma. *Blood.* 2021; 137:1318-1326. PMID: 32992341
106. Shah MR, Jan I, Johns J, Singh K, Kumar P, Belarmino N, Saggiomo KJ, Hayes C, Washington K, Toppmeyer DL, Haffty BG, Libutti SK, **Evens AM.** SARS-CoV-2 nosocomial infection: Real-world results of environmental surface testing from a large tertiary cancer center. Cancer. 2021; 127(11):1926-1932. PMID: 33599303
107. Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, El-Galaly TC, **Evens AM.** Burkitt Lymphoma International Prognostic Index.*J Clin Oncol.* 2021; 39(10):1129-1138. PMID: 33502927
108. Zayac AS, **Evens AM**, Danilov A, Smith SD, Jagadeesh D, Leslie LA, Wei C, Kim SH, Naik S, Sundaram S, Reddy N, Farooq U, Kenkre VP, Epperla N, Blum KA, Khan N, Singh D, Alderuccio JP, Godara A, Yazdy MS, Diefenbach C, Rabinovich E, Varma G, Karmali R, Shao Y, Trabolsi A, Burkart M, Martin P, Stettner S, Chauhan A, Choi YK, Straker-Edwards A, Klein A, Churnetski MC, Boughan KM, Berg S, Haverkos BM, Orellana-Noia VM, D'Angelo C, Bond DA, Maliske SM, Vaca R, Magarelli G, Sperling A, Gordon MJ, David KA, Savani M, Caimi P, Kamdar M, Lunning MA, Palmisiano N, Venugopal P, Portell CA, Bachanova V, Phillips T, Lossos IS, Olszewski AJ. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multi-center cohort study Haematologica. 2021 Feb 4. Online ahead of print. PMID: 33538152
109. **Evens AM**, Connors JM, Younes A, Ansell SM, Kim WS, Radford J, Feldman T, Tuscano J, Savage KJ, Oki Y, Grigg A, Pocock C, Dlugosz-Danecka M, Fenton K, Forero-Torres A, Liu R, Jolin H, Gautam A, Gallamini A. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. *Haematologica*. 2021 Jun 24 Online ahead of print. PMID: 34162178
110. Alderuccio JP, Olszewski AJ, **Evens AM**, Collins GP, Danilov AV, Bower M, Jagadeesh D, Zhu C, Sperling A, Kim SH, Vaca R, Wei C, Sundaram S, Reddy N, Dalla Pria A, D'Angelo C, Farooq U, Bond DA, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Kassam S, Yazdy M, Rabinovich E, Post FA, Varma G, Karmali R, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach C, Straker-Edwards A, Klein A, Blum KA, Boughan KM, Mian A, Haverkos BM, Orellana-Noia VM, Kenkre VP, Zayac A, Maliske SM, Epperla N, Caimi P, Smith SE, Kamdar M, Venugopal P, Feldman TA, Rector D, Smith SD, Stadnik A, Portell CA, Lin Y, Naik S, Montoto S, Lossos IS, Cwynarski K.
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. *Blood* Adv. 2021; 5:2852-2862. doi: 10.1182/bloodadvances.2021004458. PMID: 34283175
111. Kumar AJ, Nelson J, Rodday AM, **Evens AM**, Friedberg JW, Wildes TM, Parsons SK. Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy. *J Geriatr Oncol.* 2021 Jul 27:S1879-4068(21)00166-1. doi: 10.1016/j.jgo.2021.07.003. Online ahead of print. PMID: 34330667
112. Pearse WB, Petrich AM, Gordon LI, Karmali R, Winter JN, Ma S, Kaplan JB, Behdad A, Klein A, Jovanovic B, Helenowski I, Smith SM, **Evens AM**, Pro B. A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas. *Leuk Lymphoma*. 2021 Aug 2:1-8. Online ahead of print. PMID: 34338127
113. Orellana-Noia VM, Isaac K, Malecek MK, Bartlett NL, Voorhees TJ, Grover NS, Hwang SR, Bennani NN, Hu R, Hill BT, Mou E, Advani R, Carter J, David KA, Ballard HJ, Svoboda J, Churnetski MC, Magarelli G, Feldman T, Cohen JB, **Evens AM,** Portell C. Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. *Blood Advances.* 2021.Aug 27; Online ahead of print. PMID: 34448831
114. Lee SF, **Evens AM,** Ng AK, Luque-Fernandez MA. Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: a Hong Kong population-based study. *Science Reports.* 2021;11(1):17950. PMID: 34504223
115. Olszewski A, Kurt H, **Evens AM.** Defining and Treating High-grade B-cell lymphoma, NOS. *Blood.* 2021 Sep 15. Online ahead of print. PMID: 34525177

B. Books, Monographs and Chapters

1. **Evens, Andrew M.** andBitran, Jacob D.; Adjuvant Chemotherapy, p. 48-68. In: Perry MC, ed. Handbook of Chemotherapy. Baltimore: Lippincott Williams & Wilkins, 2001.
2. **Evens, Andrew M.** and Tallman, Martin S.; Acute Leukemias, p. 411-459. In: Skeel RT, ed. Handbook of Cancer Chemotherapy, 6th edition, Baltimore: Lippincott Williams & Wilkins, 2003.
3. Steven T. Rosen, Jane N. Winter, Leo I. Gordon, **Andrew M. Evens**, and Nicos Nicolaou. Non-Hodgkin’s Lymphoma, p. 697-748. In: Pazdur, R, Coia LR, Hoskins WJ, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach, 7th edition, 2003.
4. Steven T. Rosen, Jane N. Winter, Leo I. Gordon, **Andrew M. Evens**, and Nicos Nicolaou. Non-Hodgkin’s Lymphoma, p. 689-740. In: Pazdur, R, Coia LR, Hoskins WJ, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach, 8th edition, 2005.
5. Steven T. Rosen, Jane N. Winter, Leo I. Gordon, **Andrew M. Evens**, and Nicos Nicolaou. Non-Hodgkin’s Lymphoma, p. 697-749. In: Pazdur, R, Coia LR, Hoskins WJ, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach, 9th edition, 2006.
6. Muhajid Rizvi, **Andrew M. Evens,** Beverly P. Nelson, Steven T. Rosen. T-cell lymphoma, p 215-232. In: Marcus R, Sweetenham JW, Williams ME, eds. Lymphoma, 1st edition, Cambridge, 2007.
7. Steven T. Rosen, Jane N. Winter, Leo I. Gordon, **Andrew M. Evens**, and Nicos Nicolaou. Non-Hodgkin’s Lymphoma. In: Pazdur, R, Coia LR, Hoskins WJ, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach, 10th edition, 2007.
8. Steven T. Rosen, Jane N. Winter, Leo I. Gordon, **Andrew M. Evens**, Brian Chiu, and Nicos Nicolaou. Non-Hodgkin’s Lymphoma. In: Pazdur, R, Coia LR, Hoskins WJ, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach, 11th edition, 2008.
9. **Andrew M. Evens**, Jane N. Winter, Leo I. Gordon, Brian Chiu, and Nicos Nicolaou, Steven T. Rosen. Non-Hodgkin Lymphoma. p 695-752. In: Pazdur, R, Coia LR, Hoskins WJ, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach, 12th edition, 2009.
10. Kevin A. David, Mark Roberts, LoAnn C. Peterson, and **Andrew M. Evens.** Burkitt Lymphoma and Leukemia. Chapter 13. In: Advani A and Lazurus H, eds. Adult Acute Lymphocytic Leukemia: Biology and Treatment. Humana Press, 2010.
11. **Andrew M. Evens** and Sandra J. Horning. Hodgkin Lymphoma: Epidemiology, Diagnosis, and Treatment. pp 1375-1507. In: Vose JM, Kantarjian HM, O’Brien S. Management of Hematologic Malignancies, 2010.
12. **Andrew M. Evens,** Jane N. Winter, Leo I. Gordon, Brian C.-H. Chiu, Richard Tsang, Steven T. Rosen. [Chapter 27. Non-Hodgkin lymphoma](http://www.cancernetwork.com/cancer-management/non-hodgkin-lymphoma/article/10165/1802748). In: Haller D, Wagman LD, Camphausen KA, Hoskins WJ, eds. A Multidisciplinary Approach, 13th edition, 2010.
13. **Andrew M. Evens.** Chapter 210. Non Hodgkin’s Lymphoma. In: [Bope](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1061692) & [Kellerman](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1079596), eds. Conn's Current Therapy, 64th Edition, 2011.
14. **Andrew M. Evens,** Jane N. Winter, Leo I. Gordon, Brian C.-H. Chiu, Richard Tsang, Steven T. Rosen. [Chapter 27. Non-Hodgkin lymphoma](http://www.cancernetwork.com/cancer-management/non-hodgkin-lymphoma/article/10165/1802748). In: Haller D, Wagman LD, Camphausen KA, Hoskins WJ, eds. A Multidisciplinary Approach, 14th edition, 2011.
15. **Andrew M. Evens,** Jane N. Winter, Leo I. Gordon, Brian C.-H. Chiu, Richard Tsang, Steven T. Rosen. [Chapter 27. Non-Hodgkin lymphoma](http://www.cancernetwork.com/cancer-management/non-hodgkin-lymphoma/article/10165/1802748). In: Haller D, Wagman LD, Camphausen KA, Hoskins WJ, eds. A Multidisciplinary Approach, 15th edition, 2012.
16. **Andrew M. Evens.** Non Hodgkin’s Lymphoma. Section 13, Hematology. In: [Bope](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1061692) & [Kellerman](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1079596), eds. Conn's Current Therapy, 65th edition, 2013.
17. **Andrew M. Evens,** Jane N. Winter, Leo I. Gordon, Brian C.-H. Chiu, Richard Tsang, Steven T. Rosen. [Non-Hodgkin lymphoma.](http://www.cancernetwork.com/cancer-management/non-hodgkin-lymphoma) In: Haller D, Wagman LD, Camphausen KA, Hoskins WJ, eds. A Multidisciplinary Approach, 16th edition, 2013.
18. **Andrew M. Evens,** Jane N. Winter, Leo I. Gordon, Brian C.-H. Chiu, Richard Tsang, Steven T. Rosen. [Non-Hodgkin lymphoma.](http://www.cancernetwork.com/cancer-management/non-hodgkin-lymphoma) In: Haller D, Wagman LD, Camphausen KA, Hoskins WJ, eds. A Multidisciplinary Approach, 17th edition, 2014.
19. **Andrew M. Evens.** Non Hodgkin’s Lymphoma. Section 12, Hematology. In: [Bope](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1061692) & [Kellerman](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1079596), eds. Conn's Current Therapy, 66th edition, 2015.
20. Boris Boll and **Andrew M Evens.** The Management of Older Patients with Hodgkin Lymphoma; pp 271-286; In: Engert and Younes, eds. Hodgkin Lymphoma: A Comprehensive Overview. 2nd edition, 2015.
21. **Andrew M. Evens,** Jane N. Winter, Leo I. Gordon, Brian C.-H. Chiu, Richard Tsang, Steven T. Rosen. [Non-Hodgkin lymphoma.](http://www.cancernetwork.com/cancer-management/non-hodgkin-lymphoma) In: Haller D, Wagman LD, Camphausen KA, Hoskins WJ, eds. A Multidisciplinary Approach, 18th edition, 2015.
22. **Andrew M.** [**Evens**](http://link.springer.com/search?facet-author=%22Andrew+M.+Evens%22)and [Kristie A. Blum](http://link.springer.com/search?facet-author=%22Kristie+A.+Blum%22) (EDITORS); Non-Hodgkin Lymphoma: Pathology, Imaging, and Current Therapy; Editors: ISBN: 978-3-319-13149-8 (Print), 978-3-319-13150-4 (Online). [Cancer Treatment and Research](http://link.springer.com/bookseries/5808) 2015; 165:1-344.
23. **Andrew M. Evens.** Non-Hodgkin Lymphoma. Section 12, Hematology. In: [Bope](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1061692) & [Kellerman](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1079596), eds. Conn's Current Therapy, 1st edition, 2016.
24. **Andrew M. Evens.** Non-Hodgkin Lymphoma. Section 12, Hematology. In: [Bope](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1061692) & [Kellerman](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1079596), eds. Conn's Current Therapy, 2nd edition, 2018.
25. **Andrew M.** [**Evens**](http://link.springer.com/search?facet-author=%22Andrew+M.+Evens%22)(GUEST EDITOR); Hodgkin Lymphoma Today and Tomorrow; *British Journal of Haematology* 2019; <https://onlinelibrary.wiley.com/toc/13652141/2019/184/1>; 184:1-112.
26. Allen PB and **Evens AM;** Hodgkin lymphoma; American Society of Hematology Self-Assessment Program (ASH-SAP), Seventh Edition 2019; Chapter 22; ISBN electronic: 978-0-9789212-4-8
27. **Andrew M. Evens** and Kevin A. David. Non-Hodgkin Lymphoma. Section 12, Hematology. In: [Bope](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1061692) & [Kellerman](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1079596), eds. Conn's Current Therapy, e-book, 2020.
28. Susan K. Parsons, Joshua T. Cohen, **Andrew M. Evens.** Optimizing Decision Making in Hodgkin Lymphoma; pages 249-264. In: Engert and Younes, eds. Hodgkin Lymphoma A Comprehensive Overview. Springer. ISSN 2197-9766 ISSN 2197-9774 (electronic) Hematologic Malignancies, 2020.
29. Boris Böll, **Andrew M. Evens.** The Management of Older Patients with Hodgkin Lymphoma; pages 297-315. In: Engert and Younes, eds. Hodgkin Lymphoma A Comprehensive Overview. Springer. ISSN 2197-9766 ISSN 2197-9774 (electronic) Hematologic Malignancies, 2020.
30. Kevin A. David and **Andrew M. Evens**. Non-Hodgkin Lymphoma. Section 95, Hematology. In: [Bope](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1061692) & [Kellerman](http://store.elsevier.com/authorDetails.jsp?authorId=ELS_1079596), eds. Conn's Current Therapy, 1st edition, 2021.

C. Patents Held

1. Methods for Diagnosing and Treating B Cell Lymphomas, U.S. Serial No. 62/448,229. Date of Issue: January 18, 2016; Inventors: Dr. Andrew M. Evens and Dr. Afshin Beheshti

Shorted description: The invention provides methods for diagnosing or detecting an increased likelihood of development of cancer (e.g., B cell lymphoma) in a subject (e.g., a human patient). The methods can also be used to monitor the progression of cancer, and to monitor the progress of treatment. The methods of the invention involve detecting the level of one or more miRNAs in a sample (e.g., a blood sample) from a subject, such as a human subject. Also included in the invention are methods for preventing or treating cancer (e.g., B cell lymphoma in a subject (e.g., a human patient)).

D. Other Articles (Reviews, Editorials, etc.) In Journals; Chapters; Books; other Professional Communications

1. **Evens AM,** Lestingi TM, Bitran JD. Intermittent androgen suppression as a treatment for prostate cancer: A Review.  *The Oncologist.* 1998; 3:419-423. Peer-reviewed. PMID: 10388133
2. **Evens AM** and Gordon LI. Burkitt’s and Burkitt-like lymphoma. *Current Treatment Options in Oncology*. 2002; 3:291- 305. Invited and peer-reviewed. PMID: 12074766
3. **Evens AM** and Gartenhaus RB. Molecular etiology of mature T-cell non-hodgkin’s lymphoma. *Frontiers in Bioscience.* 2003; 8:156-175. PMID: 12456315
4. **Evens AM** and Gordon LI. Radioimmunotherapy in non-hodgkin’s lymphoma: the zevalin trials and beyond. *Clinical Lymphoma.* 2004; 5(S1):S11-5. PMID: 15498144
5. **Evens AM,** Tallman MS,Gartenhaus RB. The potential of arsenic trioxide: past, present and future. *Leukemia Research.* 2004; 28:891-900. PMID: 15234563
6. **Evens AM** and Gartenhaus RB. Treatment of T-cell non-hodgkin’s lymphoma. *Current Treatment options in Oncology.* 2004; 5:289-303. PMID: 15233906
7. **Evens AM**, Mehta J, Gordon LI. Rust and corrosion in hematopoietic stem cell transplantation:  the problem of iron and oxidative stress. *Bone Marrow Transplantation*. 2004; 34:561-71. PMID:15286699
8. **Evens AM.** Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. *Current Opinion in Oncology.* 2004; 16:576-580. PMID: 15627019
9. **Evens AM,** [Balasubramanian L](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Balasubramanian+L%22%5BAuthor%5D), [Gordon LI](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Gordon+LI%22%5BAuthor%5D). Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies. *Curr Treat Options Oncol.* 2005; 6:289-96. PMID: 15967082
10. Engel RH and **Evens AM**. Oxidative stress and apoptosis: a new treatment paradigm in cancer. *Front Biosci.* 2006; 11:300-12. PMID: 16146732
11. Rizvi MA, **Evens AM**, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin's lymphoma. *Blood.* 2006; 107:1255-64. Peer-reviewed. PMID: 16210342
12. [Balasubramanian L](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Balasubramanian+L%22%5BAuthor%5D), **Evens AM.** Targeting angiogenesis for the treatment of sarcoma. *Curr Opin Oncol*. 2006; 18:354-9. Peer-reviewed. PMID: 16721130
13. **Evens AM,** Gordon LI, Rosen ST, Winter JN. Update on approaches to the treatment of follicular lymphoma*. Oncology Special Edition.* 2006; 9:113-120. Invited.
14. [**Evens AM,** Querfeld C, Rosen ST](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16704170&query_hl=1&itool=pubmed_docsum)**.** T-cell non-Hodgkin's lymphoma. *Cancer Treat Res.* 2006; 131:161-220. PMID: 16704170
15. **Evens AM,** Hutchings M, Diehl V. Systemic treatment of Hodgkin lymphoma. *PPO Updates, Principles & Practice of Oncology*. 2007; 21:1-13. Peer-reviewed.
16. **Evens AM** and Winter JN. Update on Approaches to the treatment of follicular lymphoma. *Oncology Special Edition.* 2007; 9:1-13.
17. David KA, Mauro L, **Evens AM.** Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options. *Curr Treat Options Oncol.* 2007; 8:352-74. PMID: 18214690
18. **Evens AM,** Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nature Clinical Practice Oncology. 2008; 5:543-56. PMID: 18679394
19. **Evens AM** Chiu BC. [The challenges of epidemiologic research in non-Hodgkin lymphoma.](http://www.ncbi.nlm.nih.gov/pubmed/18984897?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) *JAMA.* 2008; 300:2059-61. PMID: 18984897
20. **Evens AM,** Sweetenham JW, Horning SJ. [Hodgkin lymphoma in older patients: an uncommon disease in need of study.](http://www.ncbi.nlm.nih.gov/pubmed/19086599?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum) *Oncology* (Williston Park). 2008; 22:1369-79; discussion 1379, 1385, 1388-93; PMID: 19086599
21. KelemenK, Cao W, Peterson LC, **Evens AM,** Variakojis D. Primary mediastinal large B-cell lymphoma in HIV: report of two cases. *Journal of Hematopathology.* 2009; 2:45. Peer-reviewed. PMID: 19669223
22. **Evens AM,** Wagner LI. C[uring Hodgkin's lymphoma: quantity and quality.](http://www.ncbi.nlm.nih.gov/pubmed/19959071?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=3) *Lancet Oncology.* 2009; 10:1134-5. PMID: 19959071
23. **Evens AM,** Smith SM. [Reply to D. Dierickx et al.](http://www.ncbi.nlm.nih.gov/pubmed/20479420) *Journal of Clinical Oncology.* 2010 May 17. [Epub ahead of print].
24. [**Evens AM**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Evens%20AM%22%5BAuthor%5D)**.** Improving outcomes in PTLD. Oncology (Williston Park). 2010 Sep; 24:944, 946-. PMID: 21138176
25. Feliciano J, Moll MZ, **Evens AM.** Novel Targeted Agents for the Treatment of Hodgkin Lymphoma. CML – *Leukemia & Lymphoma* 2010; 18:1–11.
26. Ahmed S, Winter JN, Gordon LI, **Evens AM.**  [Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.](http://www.ncbi.nlm.nih.gov/pubmed/20470217) *Leukemia & Lymphoma.* 2010; 51:1163-77. PMID: 20470217
27. Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, **Evens AM.** Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. *Oncology* (Williston Park). 2010; 24:574-87. PMID: 20669794
28. **Evens AM,** Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. *Current Oncology Reports.* 2010; 12:383-94. PMID: 20963522
29. **Evens AM.** Intergroup Study Evaluates Outcomes of Elderly vs Younger Patients Treated for Advanced Hodgkin Lymphoma. *ASCO Post.* July 15, 2011, Volume 2, Issue 11.
30. Jagadeesh D, Woda BA, Draper J, **Evens AM.** [Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations.](http://www.ncbi.nlm.nih.gov/pubmed/22241590) *Curr Treat Options Oncol*. 2012. PMID: 22241590
31. Al-Mansour Z, Nelson BP, **Evens AM.** Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies. *Current Hematologic Malignancies Report;* 2013; Jun 5. [Epub ahead of print], Peer-reviewed. PMID: 23737188
32. Jagadeesh D, Diefenbach C, **Evens AM.** Hodgkin Lymphoma in Older Patients: Challenges and Opportunities to Improve Outcomes; *Hematol Oncol.* 2013; 31 Suppl 1:69-75 Peer-reviewed. PMID: 23775654
33. Al-Mansour Z, Nelson BP, **Evens AM.** Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies. *Current Hematologic Malignancies Report.* 2013; 8:173-83. Peer-reviewed. PMID: 23737188
34. **Evens AM** and Hong F. How can Outcomes be Improved for Older Hodgkin Lymphoma Patients? *Journal of Clinical Oncology* 2013; 31:1502-5. Peer-reviewed. PMID: 23509323
35. **Evens AM** CAR T-Cell Therapy in Cancer: Driving Toward the Clinic; *The ASCO Post;* December 1, 2014, Volume 5, Issue 19.
36. Reddy NM, **Evens AM.** Chemotherapeutic advancements in peripheral T-cell lymphoma *Seminars in Hematology.* 2014; 51:17-24. Peer-reviewed. PMID: 24468312
37. Kostakoglu L and **Evens AM.** FDG-PET Imaging for Hodgkin Lymphoma: Current Use and Future Applications. *Clinical Advances in Hematology & Oncology*. 2014; 12:20-35. PMID: 25000313
38. **Evens AM**, Kostakoglu L. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. *Blood.* 2014 Nov 27; 124:3356-64. Peer-reviewed. PMID: 25428223
39. Kritharis A, Sharma J, **Evens AM**. Current therapeutic strategies and new treatment paradigms for follicular lymphoma. *Cancer Treat Res.* 2015; 165:197-226. Peer-reviewed. PMID: 25655611
40. **Evens AM**, Kostakoglu L. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. *Hematology ASH Education Program*. 2014 Dec 5;2014 (1):135-43; Peer-reviewed. PMID: 25696846
41. Kritharis A, Coyle M, Sharma J, **Evens AM**. Lenalidomide in non-Hodgkin lymphoma: biologic perspectives and therapeutic opportunities. *Blood.* 2015; 125(16):2471-6; Peer-reviewed. PMID: 25736312
42. Coyle M, Kostakoglu L, **Evens AM**. The evolving role of response-adapted PET imaging in Hodgkin lymphoma. *Ther Adv Hematol.* 2016 Apr;7(2):108-25. PMID: 27054026
43. Kritharis A, Pilichowska M, **Evens AM**. How I manage patients with grey zone lymphoma. British Journal of Haematology. 2016; 174:345-50. Peer-reviewed. PMID: 27301470
44. David KA, Kritharis A, **Evens AM**. Does Q fever contribute to pathogenesis of non-Hodgkin lymphoma? *Lancet Haematol.* 2018 May;5(5):e186-e187. PMID: 29650494
45. **Evens AM.** Important new developments in Hodgkin Lymphoma. *Br J Haematol.* 2019 Jan;184(1):6. doi: 10.1111/bjh.15736. No abstract available. PMID: 30589096
46. **Evens AM**, Carter J, Loh KP, David KA. Management of older Hodgkin lymphoma patients. Hematology Am Soc Hematol Educ Program (*Blood*). 2019; 2019:233-242. PMID: 31808898
47. Carter J, David KA, Kritharis A,**Evens AM.** Current Treatment Options for Older Patients With Hodgkin Lymphoma. *Curr Treat Options Oncol.* 2020 Apr 23;21(5):42. PMID: 32328822
48. Hokland P, Shah M, David K,**Evens A**, Auer R, Ledieu R, Kreissl S, Bröckelmann PJ, Borchmann P, Korula A, Mathews V, Owattanapanich W, Trotman J. How I Treat Advanced Hodgkin Lymphoma - A Global View. Br J Haematol. 2020 Jun 19. doi: 10.1111/bjh.16587.
49. **Evens AM,** Parsons SK. Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality*. J Clin Oncol.* 2020; doi: 10.1200/JCO.20.02668. Epub ahead of print. PMID: 33030980.
50. Shah MR, Brandt JS, David KA, **Evens AM.** Lymphoma Occurring During Pregnancy: Current Diagnostic and Therapeutic Approaches. *Curr Oncol Rep.* 2020 Aug 17;22(11):113. PMID: 32804274
51. **Evens AM.** Highlights in Hodgkin lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. *Clin Adv Hematol Oncol.* 2021; 19 Suppl 7(2):20-23. PMID: 33843922

E. Abstracts (research poster presentations): \***last 5 years, peer reviewed only (of 290+)**\*

1. Coyle ME, Dashnamoorthy R, Beheshti A, **Evens AM**. **Transcriptomic profiling of response to PI3K inhibition by BKM120 in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL). International Conference on Malignant Lymphoma (ICML)**: **2015**, **Lugano, Switzerland; #**266.
2. **Evens AM,** Dashnamoorthy R, Beheshti A, Abermil N, Sharma J, Coyle M, Kandela I, Mazar A, Hlatky L, Gartenhaus RB. **MYC and CHK1 Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models With Anti-Proteasomal Therapy. International Conference on Malignant Lymphoma (ICML)**: **2015**, **Lugano, Switzerland;** #190.
3. Rosenberg A, Klein AK, Ruthazer R, **Evens AM.** **Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder (HL-PTLD): A Comparative Analysis of Prognosis and Survival**. **International Conference on Malignant Lymphoma (ICML)**: **2015**, **Lugano, Switzerland**; #179.
4. Henderson TO, Parsons SK, Wroblewski K, Chen L, Hong F, Smith SM, McNeer J, Advani R, Gascoyne R, Constine L, Horning SJ, Bartlett NL, Shah BD, Connors JM, Leonard J, Kahl BS, Kelly K, Schwartz C, Friedman DL, Gordon LI, **Evens AM.** Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis. Blood (ASH) 2015; 126 (23):2635.
5. Kelly MJ, Parsons SK, Hodgson DC, Cohen JT, Yeh JM, Abramson JS, Friedman DL, Henderson TO, Johnson PW, Pauker SG, Raemaekers JM, Winter JN, Kelly KM, Meyer RM, Castellino SM, **Evens AM.** An Adjustable Markov Model to Project Life Expectancy (LE) for EarlyStage Favorable Risk Hodgkin Lymphoma Patients Treated with Contemporary Therapy; Blood (ASH) 2015; 126 (23):2636
6. Petrich AM, Barta SK, Lansigan F, Wang T, Bhatt A, Wasp G, Hill A, Passero FC, Kahalon A, Kansara RR, Gandhi M, Slack GW, Feldman T, **Evens AM,** Savage KJ.Retrospective Analysis of Lymphomas in the Setting of Autoimmune Disease and the Impact of Immunosuppression. Blood (ASH) 2015; 126 (23):2637.
7. Kritharis A, McDonald JT, Beheshti A, Pilichowska M, Burgess K, Ricks-Santi L, McNiel E, Dashnamoorthy R, **Evens AM.**A Comparative Oncology Analysis of Canine T-Cell Lymphoma (TCL): Immunohistochemical Study and Next Generation Sequencing for Protein Analysis and Genomic Target Discovery. Blood (ASH) 2015; 126 (23):3883.
8. Passero FC, Dashnamoorthy R, Beheshti A, Hlatky L, Abermil N, Coyle ME, Sharma J, **Evens AM.** The Proteasome Inhibitor, Ixazomib, Combined with Novel Drug Combinations in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Identification of Key Genes and Signaling Pathways Via a Novel Systems Biology Approach. Blood (ASH) 2015; 126 (23):2753.
9. Dashnamoorthy R, Beheshti A, Abermil N, Lansigan F, Kinlaw W, Gartenhaus R, Jones G, Hlatky L, **Evens AM**.Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL): Fatty Acid Synthase (FASN) and PI3K Dependent Cell Death Identifies a Novel Therapeutic Paradigm. Blood (ASH) 2015; 126 (23):1283.
10. Coyle ME, Dashnamoorthy R, Beheshti A, **Evens AM.** The PI3 Kinase (PI3K) Inhibitor, Buparlisib/BKM120, in B-Cell, T-Cell and Hodgkin Lymphoma Cell Lines: Cell Death Studies and Examination of Genomic Pathway Analyses Via a Systems Biology Approach. Blood (ASH) 2015; 126 (23):1555.
11. Beheshti A, Neuberg DS, McDonald JT, **Evens AM.** The Impact of Age and Sex in DLBCL: Determination of Biologic Dynamics and Delineation of Inter-Connected Signaling Networks Via a Systems Biology Analysis. Blood (ASH) 2015; 126 (23):2672.
12. Linendoll N, Saunders T, Burns R, Nyce J, Wendell K, **Evens AM,** Parsons SK. Health-related quality of life (HRQL) in Hodgkin lymphoma (HL): A systematic review (SR). J Clin Oncol (ASCO); 34, 2016; suppl 3S; abstr 234.
13. Passero FC, Beheshti A, Dashnamoorthy R, **Evens AM.** Proteasome Inhibitor Therapy in Hodgkin Lymphoma: Leveraging Systems Biology Analyses for Cell Specific Transcriptome Alterations and Optimum Combinatorial Therapy. 10th International Symposium on Hodgkin Lymphoma; Cologne, Germany, October 2016; 041a
14. Kelly MJ, Parsons SK, Cohen JT, Castellino S, Kelly KM, Keller F, Henzer TJ, Kumar A, Johnson P, Meyer RM, Morton LM, Radford J, Raemaekers J, Hodgson DC, **Evens AM.** Construction of a Decision Tool to Aid Treatment Choices for Early Stage Hodgkin Lymphoma (ES HL): Bringing Survivorship Forward. 10th International Symposium on Hodgkin Lymphoma; Cologne, Germany, October 2016; 056a
15. Friedberg JW, **Evens AM,** Press OW. Long-Term Follow-up of SOWG 0816: Response-Adapted Therapy of Advanced Stage Hodgkin Lymphoma Using Early Interim FDG-PET Imaging. 10th International Symposium on Hodgkin Lymphoma; Cologne, Germany, October 2016; 03a (oral presentation).
16. **Evens AM,** Hamlin PA, Nabhan C, Advani RH, Fanale M,Petrich A, Smith SM, Bociek G, Winter J, Gordon LI. Sequential Brentuximab Vedotin (BV) and Adriamycin, Vinblastine, and Dacarbazine (AVD) for Older Patients with Untreated Hodgkin Lymphoma (HL): Findings from a Phase II Window Study. 10th International Symposium on Hodgkin Lymphoma; Cologne, Germany, October 2016; 01a.
17. Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Gupta G, Kritharis A, Gascoyne RD, **Evens AM,** Jaffe ES. Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Characteristics, Outcomes, and Prognostication Among A Large Multicenter Cohort. 10th International Symposium on Hodgkin Lymphoma; Cologne, Germany, October 2016; 04a.
18. Zhang J, **Evens AM,** Dave S. Integrative Genetic and Clinical Analysis through Whole Exome Sequencing in 1001 Diffuse Large B Cell Lymphoma (DLBCL) Patients Reveals Novel Disease Drivers and Risk Groups; Blood (ASH) 2016; 128 (22):1087a (oral presentation).
19. Beheshti A, Coyle ME, Dashnamoorthy R, **Evens AM.** Buparlisib/BKM120 PI3 Kinase Therapy in B Cell and T Cell Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma (HL): Identification of Resistance Pathways and Biomarker Discovery. Blood (ASH) 2016; 128 (22):2920a.
20. Passero FC, Dashnamoorthy R, Beheshti A, McDonald JT, **Evens AM.** Proteasome and HDAC Inhibitor Therapy in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL): Nuclear Factor Erythroid 2 like 2 (NRF2)-Dependent Cell Death and Function. Blood (ASH) 2016; 128 (22):3020.
21. Fu, J, Upshaw J, Kelly MJ, Cohen JT, Saunders S, **Evens AM,** Parsons SK. Assessing the Risk of Cardiac Toxicity after Contemporary Treatment for Hodgkin Lymphoma (HL): A Multidisciplinary Systematic Review. Blood (ASH) 2016; 128 (22):3564.
22. Beheshti A, Vanderburg C, Mcdonald JT, Zhang H, **Evens AM.** Circulating microRNAs Predict the Initiation of NHL in a Novel In Vivo Model: Impact of Age and Sex Via a Systems Biology Approach. Blood (ASH) 2016; 128 (22):4114.
23. **Evens AM** and E Jaffe. Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study. Blood (ASH) 2016; 128 (22):4145.
24. Dashnamoorthy R, Beheshti A, Sarkar S, Sabhachandani P, Passero FP, Purvey S, Boissel L, Konry T, **Evens AM.** CD19 Target Activated Natural Killer (CD19.TaNK) Cellular Therapy: A Novel immunotherapeutic Approach to the Treatment of Non-Hodgkin Lymphoma (NHL). Blood (ASH) 2016; 128:4174.
25. Zhang J et al and Sandeep Dave. Integrative Analysis of 1001 Diffuse Large B Cell Lymphoma Identifies Novel Oncogenic Roles for Rhoa; Blood (ASH) 2017; 130 (24):37 (oral presentation).
26. Dashnamoorthy R et al **and Evens AM.**Harnessing Microfluidic Single Cell (MF-SC) and 3D “Organ-on-Chip” Assay Technologies for the Investigation of Immunotherapy and Study of Tumor Microenvironment (TME) in Antibody-Resistant Non-Hodgkin Lymphoma (NHL); Blood (ASH) 2017; 130 (24):1473.
27. Dashnamoorthy R et al and **Evens AM.**The Immune Checkpoint Receptors PD-1, PD-L1, TIM-3 and LAG-3 in Lymphoma:  Tumor Cell and Tumor Infiltrating Lymphocyte (TIL) Expression, Patient Prognostication, and Identification of Rational Therapeutic Targets; Blood (ASH) 2017; 130 (24):2750.
28. Hill BT et al and Kahl BS.Maintenance Rituximab or Observation after Frontline Treatment with Bendamustine-Rituximab (BR) for Follicular Lymphoma: A Real World Analysis Across 13 US Cancer Centers; Blood (ASH) 2017; 130 (24):2779.
29. Hsi ED et al and Press OW.Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL):  a SWOG S0816 US Intergroup Correlative Study; Blood (ASH) 2017; 130 (24):4003.
30. Beheshti A et al and **Evens AM.**Circulating Micrornas (miRNA) As a Novel Liquid Biopsy and Therapeutic Platform in MYC and Non-MYC Diffuse Large B-Cell Lymphoma (DLBCL); Blood (ASH) 2017; 130 (24):4005.
31. Badar T et al and Costa LJ.Efficacy of Salvage Chemotherapy in Diffuse Large B Cell Lymphoma with Primary Treatment Failure According to Putative Cell of Origin Blood (ASH) 2017; 130 (24):4141.
32. **Evens AM,** Advani RH, Helenowski I, Fanale M, Smith SM, Jovanovic B, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA. Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results. J Clin Oncol (ASCO) 2018; 36, 2018; abstr 7541.
33. Potential impact of consolidation radiation therapy for advanced Hodgkin Lymphoma: a secondary modeling analysis of SWOG S0816. Ha CS, Li H, Schoder H, Pinnix C, Brem E, Bartlett N, **Evens A,** Hsi E, Rimsza L, Leonard JP, Kahl BS, LeBlanc M, Smith S, Constine L, Friedberg JW; 11th International Symposium on Hodgkin Lymphoma (ISHL11), October 2018; Cologne, Germany.
34. A multicenter phase 2 study of sequential brentuximab vedotin and AVD chemotherapy for older patients with untreated classical Hodgkin Lymphoma. **Evens AM,** Advani RH, Helenowsk I, Fanale M, Smith SM, Jovanovic B, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA; 11th International Symposium on Hodgkin Lymphoma (ISHL11), October 2018; Cologne, Germany.
35. A clinicopathologic consensus study of gray zone Lymphoma (GZL) with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical HL (cHL). Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, **Evens AM;** 11th International Symposium on Hodgkin Lymphoma (ISHL11), October 2018; Cologne, Germany.
36. A phase II study of pembrolizumab (pem) followed by AVD for frontline treatment of classical Hodgkin Lymphoma (cHL): interim results. Allen PB, **Evens AM,** Pro B, Karmali R, Savas H, Dillehay G, Rademaker A, Palmer B, Advani R, Gordon LI, Winter JN; 11th International Symposium on Hodgkin Lymphoma (ISHL11), October 2018; Cologne, Germany.
37. Patterns and outcomes with salvage treatment for Hodgkin Lymphoma (HL) in the modern era: a real-world analysis from the community oncology setting in the United States. Kumar AJ, Chao CR, Rodday AM, Cannizzaro NT, Rodriguez R, Feliciano J, **Evens AM**, Parsons SK; 11th International Symposium on Hodgkin Lymphoma (ISHL11), October 2018; Cologne, Germany.
38. Ultra-Sensitive Detection of Circulating Serum microRNAs (miRNAs) in Diffuse Large B-Cell Lymphoma (DLBCL) Patient-Derived Xenograft (PDX) Models and Correlation with Disease Status in DLBCL Patient. Beheshti B and **Evens AM**; Blood (ASH) 2018, 132:2973.
39. The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imid® Continuation (BIONIC) Study. Baratto L and **Evens AM.** Blood (ASH) 2018, 132:1615.
40. Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. Mato A and Eichhorst B. Blood (ASH) 2018, 132:4759.
41. A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408 Hong F, **Evens AM** and Thanarajasingam G. Blood (ASH) 2018, 132:4157.
42. Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival. Winter AM, and **Evens AM,**Kahl BS, Hill BT. Blood (ASH) 2018, 132:4146.
43. Transcriptomic Systems Biology Analyses with Buparlisib (BKM120) Pan PI3K Inhibition in Canine B Cell Lymphoma (BCL): Leveraging Comparative Oncology for Cancer Therapeutics and Biomarker Discovery. Ravi D and **Evens AM.** Blood (ASH) 2018, 132:4114.
44. Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis. Ha C and Friedberg JW. Blood (ASH) 2018, 132:2927.
45. The Development and Validation of an Electronic Health Record (EHR)-Based Algorithm for Identifying Treatment Failure in Newly Diagnosed Hodgkin Lymphoma (HL) Treated in a US Community Oncology Setting. Chao CR, and **Evens AM,** Parsons SK. Blood (ASH) 2018, 132:2261.
46. Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. **Evens AM** and Gallamini A. Blood (ASH) 2018, 132:1618.
47. Systems Biology Analyses to Delineate Mechanisms of Anti-CD20 Antibody Resistance in Non-Hodgkin Lymphoma (NHL): Influence of BCR Signaling and the Critical Importance of Calcium Polarization. Ravi D and **Evens AM**. Blood (ASH) 2018, 132:1665.
48. A Phase II Study of Sequential Pembrolizumab (PEM) Followed By AVD for Frontline Treatment of Classical Hodgkin Lymphoma (CHL): Quantifying Response Following PEM Monotherapy with FDG-PET-Derived Metabolic Tumor Volume and Total Lesion Glycolysis. Savas H and Winter JN. Blood (ASH) 2018, 132:1651.
49. Dashnamoorthy R, Sarkar S, Beheshti A et al and **Evens AM**. Transcriptomic and Metabolomic Profiling Identifies Calcium-Dependent Signaling Mechanisms As a Novel and Exploitable Target to Overcome Anti-CD20 Resistance in Non-Hodgkin Lymphoma (NHL). Blood (ASH) 2019, 133:1511.
50. Rodday A, Hahn T, Kumar A, et al (2nd to last author). Treatment with Full Chemotherapy Regimens in Older Adults with Hodgkin Lymphoma Improves 3-Year Overall Survival, but Less Than Half Receive Full Regimens. Blood (ASH) 2019, 133:1563.
51. Dashnamoorthy R, Beheshit A, Su X, et al and **Evens AM**. Identification of FASN-Dependent Onco-Metabolic Regulation of the Pentose Phosphate Pathway (PPP) and Nucleotide Metabolism in Non-Hodgkin Lymphoma (NHL). Blood (ASH) 2019, 133:1573.
52. Sullivan K, Toscani M, Poretta T, et al and **Evens AM**. Shared Decision Making in Cancer Treatment: Findings from a Large Survey of Lymphoma (LYM) Patients and Survivors. Blood (ASH) 2019, 133:2134.
53. Orellana-Noia V, Isaac K, Wages N, et al (2nd to last author). Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. Blood (ASH) 2019, 133:4027.
54. David K, Pulitzer M, Guitart J, et al (2nd to last author). Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy. Blood (ASH) 2019, 133:4028.
55. Olszewski AJ, Lossos IS, Stadnik A, Smith SD, Jagadeesh D, Kim S-H, Phillips TJ, Naik S, Feldman T, Reddy N, Sundaram S, Maliske S, Kenkre V, Epperla N, Savani M, Portell C, Palmisiano N, Klein AK, **Evens AM.** Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites. J Clin Oncol (ASCO); 38, 2020; suppl 15; abstr 8043.
56. Parsons SK., Bhakta N, Rodday AM, Scharman C, André M, Federico M, Friedberg JW, Friedman DL, Gallamini A, Hay AE.,. Kahl BS, Keller FG, Kelly KM, Meyer RM, Raemaekers J, Robison LL, Hudson MM, Cohen JT, **Evens AM,** Wong FL. Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC). J Clin Oncol (ASCO); 38, 2020; suppl 15; abstr 12068.
57. Jagadeesh D, Tsai DE, Wei W, Bustamante JA, Wagner-Johnston ND, Berg S, Kim S-H, Reddy NM, Sriram D, Portell C, Ghione P, Voorhees T, Kamdar MK, Koff JL, Dharnidharka V, **Evens AM.** Post-transplant lymphoproliferative disorder (PTLD) after solid organ transplant (SOT): A multicenter real world analysis (RWA) of 877 patients (pts) treated in the modern era. J Clin Oncol (ASCO); 38, 2020; suppl 15; abstr e20026.
58. Parsons SK, Rodday AM, Scharman C, André M, Federico M, Friedberg JW, Friedman DL, Gallamini A, Hay AE, Hoskin P, Johnson P, Kahl BS, Keller FG, Kelly KM, Meyer RM, Radford JA, Raemaekers J, Zinzani PL, Cohen JT, **Evens AM.** The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL). J Clin Oncol (ASCO); 38, 2020; suppl 15; abstr e20019.
59. **Evens A,** Advani R, Aleman B, Andre M, Bhakta N, Cardoso M, Castellino S, Cerhan J, Chao C, Cohen J, Cole P, Engert A, Federico M, Figueroa L, Flerlage J, Flowers C, Fortpied C, Friedberg J, Friedman D, Gallamini A, Gutierrez M, Hahn T, Hay A, Henderson T, Hodgson D, Hoppe B, Hoppe R, Hoskin P, Hudson M, Hutchings M, Johnson P, Keller F, Kelly K, Kostakoglu L, Kumar A, Link B, Link M, Mailhot R, Meyer R, Morton L, Ng A, Radford J, Raemaekers J, Robison L, Rodday AM, Savage K, Schwartz C, Specht L, Straus D, Upshaw J, van Leeuwen F, Volchenboum S, Warwick L, Wong J, Wong L, Zinzani PL, Parsons S. The Hodgkin Lymphoma International Study for Individual Care (HOLSTIC): A Multi-National Collaborative to Enhance Decision Making for Pediatric and Adult Hodgkin Lymphoma (HL). EHA Library (European Hematology Association); 06/12/20; 293638; abstract EP1149.
60. Moore JA, **Evens AM**, Newberg J, Severson EA, Mills J, PhD, Carter J, Matnani R, Vergilio J-A, Trabucco SE, Ganesan S. Genomic Ancestry in B Cell Lymphoid Malignancies. December 2020 ASH Annual Meeting. Abstract 1102.
61. Galvez C, Karmali R, Hamadani M, Gordon LI, Winter JN, Ma S, Nelson V, Palmer BA, Fenske TS, Shah NN, Jagadeesh D, Klein A, Helenowski I, Jovanovic B, Petrich AM, **Evens AM,** Pro B. A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen. December 2020 ASH Annual Meeting. Abstract 1190.
62. Perez GK, Hong F, **Evens AM**., Habermann TM, Advani R, Ansell SM, Cheema PS, Dy PA, O'Brien TE, Winter JN, Chang JE, Cella D, Kahl BS, Wagner LI.Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. December 2020 ASH Annual Meeting. Abstract 2046.
63. Rodday AM,Parsons SK, Scharman C, Advani R, Federico M, Friedberg JW, Gallamini A, Hodgson DC, Hoskin, Hutchings M, Johnson P, Kelly KM, Link BK, Radford JA, Zinzani PL, Cerhan JR, Raemaekers J, **Evens AM**, and On Behalf Of The HoLISTIC Consortium. Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. December 2020 ASH Annual Meeting. Abstract 2066.
64. Shah MR, Jan I, Johns J, Singh K, Kumar P, Belarmino N, Saggiomo K, Hayes C, Toppmeyer D, Washington K, Haffty B, Libutti S, **Evens, AM**. Environmental Sars-Cov-2 Surface Testing: Low Incidence of Virus Positivity in Outpatient and Inpatient Hematology/Oncology Settings. December 2020 ASH Annual Meeting. Abstract 2478.
65. Kumar AJ,Nelson J, Rodday AM, **Evens AM**, Friedberg JW, Wildes TM, Parsons SK. Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL). December 2020 ASH Annual Meeting. Abstract 2503.
66. Larose MI, Bair SM, Manjunath S, Carter J, **Evens AM**, Isaac K, Portell CA, Chowdhury S, Epperla N, Intrator J, Feldman TA., Saeed H, Isenalumhe L, Landsburg DJ, Nasta SD, Gerson JN, Barta SK, Chong EA, Schuster SJ, Paydar I, Plastaras J, Svoboda J. Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis. December 2020 ASH Annual Meeting. Abstract 2978.
67. AgrawalP, David KA, Chen Z, Sundaram S, Kim S-H, Vaca R, Lin Y, Singer S, Malecek M-K, Carter J, Zayac A, Kim MS, Reddy N, Habib A, Strouse C, Graber J, Bachanova V, Tsang M, Major A, Bond DA, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Glantz M, Goldlust S, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon SE, Sieg AG, Cleveland J, Epperla N, Karmali R, Naik S, Smith SM, Rubenstein JL, Kahl BS, Chadburn A, **Evens AM,** Martin P. EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. December 2020 ASH Annual Meeting. Abstract 3051.

F. Reports

* 1. Rizvi MA, Spies SM, **Evens AM.** A Patient With Relapsed Rituximab-Refractory Follicular Lymphoma Treated Wtih Motexafin Gadolinium and Yttrium-90 Ibritumomab Tiuxetan. Case Studies in Lymphoma 2005; 3:1-6.
	2. Multiple successful desensitizations to brentuximab vedotin: a case report and literature review. Devita MD, **Evens AM,** Rosen ST, Greenberger PA, Petrich AM. Journal National Comprehensive Cancer Network. 2014; 12:465-71. PMID: 24717566
	3. Shah U, Kritharis A, **Evens AM**. Paraneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative disorder. Annals of Hematology. 2014 Dec 18. [Epub ahead of print] No abstract available. PMID: 25516456
	4. English R, Ashrafi A, **Evens AM**, Oreadi D. A Clinico-Pathologic Correlation. Burkitt's lymphoma. Journal of the Massachusetts Dental Society. 2015; 1:34-36. PMID: 26168531
	5. Goldstein N, Kritharis A, Coyle M,  Singh M,  Miller KB; and **AM Evens.** [Atypical Infectious Complications as Adverse Events Due to Ibrutinib](http://www.bloodjournal.org/content/125/16/2497/tab-e-letters#atypical-infectious-complications-as-adverse-events-due-to-ibrutinib). Blood e-letter; 2015. <http://www.bloodjournal.org/content/125/16/2497/tab-e-letters>

**PRESENTATIONS:**

***Scientific (peer reviewed Oral/Plenary research conference presentations):***

1. **AM Evens**, et al. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant epoetin: A follow-up report from the Research on Adverse Drug Events and Reports (RADAR) project. American Society of Clinical Oncology (ASCO), 40th Annual Meeting. New Orleans, LA, June 2004.
2. **AM Evens** et al. Motexafin Gadolinium (MGd) Induces Significant Cytotoxicity Through Caspase-Dependent Apoptosis in Lymphoma Cell Lines.  Sixth International Symposium on Hodgkin’s Lymphoma. Cologne, Germany, September 2004.
3. **AM Evens,** et al.FDA Policies Should Be Amended To Allow Pharmaceutical Manufacturers To Disseminate Information Regarding Potentially Fatal Toxicities That Occur with Off-Label Use of Oncology Agents: A Policy Recommendation Based on Review of Thalidomide-Associated Thromboembolism Cases by the RADAR Project. American Society of Hematology (ASH), 46th Annual Meeting. San Diego, CA, December 2004.
4. **AM Evens,** J Cilley, T Ortiz, M Gounder, S Miyata, K Catsaros, F Rademaker, JN Winter, LI Gordon. Granuloctye-colony stimulating factor (GF) is not necessary and may be harmful in Hodgkin's disease (HD) treated with ABVD: high dose intensity (DI), low toxicity, 94% progression free (PFS) and 98% overall survival (OS) without GF in a 10-year analysis. American Society of Clinical Oncology (ASCO), 42nd Annual Meeting. Atlanta, Georgia, June 2006.
5. KR Carson, **AM Evens,** et al. Progressive Multifocal Leukoencephalopathy Associated with Rituximab Treatment of B-Cell Lymphoproliferative Disorders: A Report of 29 Cases from the RADAR Project. [370] Session Type: Oral Session. American Society of Hematology (ASH), 49th Annual Meeting. Atlanta, GA; December 2007.
6. **AM. Evens** et al**.** Yttrium-90 ibritumomab tiuxetan combined with the novel expanded porphyrin motexafin gadolinium (MGd, Xcytrin) produces rapid and sustained complete remissions in patients with rituximab-refractory follicular lymphoma: final results of a phase I/II clinical trial. [17] 10th International Conference on Malignant Lymphoma; Lugano, Switzerland; June 2008.
7. **AM Evens,** et al. Expression of Hypoxia-Inducible Factor (HIF) Is An Independent Favorable Prognostic Factor in Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP. [479] Session Type: Oral Session. American Society of Hematology (ASH), 50th Annual Meeting. San Francisco, CO; December 2008.
8. **AM Evens,** et al. Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors. [8510] Session Type: Oral Session. American Society of Clinical Oncology (ASCO), 45th Annual Meeting. Orlando, Florida, June 2009.
9. S Bhalla, R Gartenhaus, B Dai, S Prachand, A Mukherjee, RL Elstrom, LI Gordon, and **AM Evens.** The Novel 2nd Generation Small Molecule MEK Inhibitor, AZD-6244, Induces Cell Death in Lymphoma Cells Lines, Primary Cells, and in a Human Lymphoma Xenograft Model. Blood (ASH Annual Meeting Abstracts), December 2009; 114:285.
10. Loughran TP, Yao X, PhD, Bennett JM, Litzow MR, **Evens AM,** Tallman MS. Results of a Prospective Multicenter Phase II Study of Initial Treatment with Methotrexate In LGL Leukemia (ECOG Protocol E5998). Blood (ASH Annual Meeting Abstracts), Dec 2010; 115:702.
11. **AM Evens,** et al. The Impact of Race and Place of Birth on Incidence and Survival: A Comprehensive Analysis of the United States (US) Hodgkin Lymphoma (HL) SEER Database. Abstract 010.11th International Conference on Malignant Lymphoma (11-ICML); Lugano, Switzerland, June 15-18, 2011.
12. **AM Evens,** et al. Primary Central Nervous System (CNS) Post-Transplant Lymphoproliferation (PTLD): An International Report of 52 Cases in the Rituximab Era. Abstract 054. 11th International Conference on Malignant Lymphoma (11-ICML); Lugano, Switzerland, June 15-18, 2011.
13. **AM Evens,** et al. Efficacy and Tolerability of ABVD and Stanford V for Elderly Advanced-Stage Hodgkin Lymphoma (HL): Subset Analysis from the Phase III Randomized US Intergroup Trial E2496. Abstract 107. 11th International Conference on Malignant Lymphoma (11-ICML); Lugano, Switzerland, June 15-18, 2011.
14. **AM Evens,** et al. A Novel Small Molecule MEK Inhibitor Induces Cell Death Through a BIM-Dependent Mechanism in non-Hodgkin Lymphoma (NHL) Cell Lines, Primary Cells, and a Human NHL Xenograft Model.Abstract 156.11th International Conference on Malignant Lymphoma; Lugano, Switzerland, June 15-18, 2011.
15. **AM Evens,** et al. Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era. Blood (ASH Annual Meeting Abstracts), Dec 2011; 118:879.
16. **AM Evens,** et al. Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. Blood (ASH Annual Meeting Abstracts), Dec 2011; 118:94.
17. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, **Evens AM,** et al. ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphoma. *Blood* (ASH Annual Meeting Abstracts) 2012; 120:898.
18. **AM Evens et al.** A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL). *Blood* (ASH Annual Meeting Abstracts) 2012 120:55.
19. Bednarik J and **Evens AM.** Hepatitis B Virus (HBV) Screening in Hematology/Oncology Patients Who Receive Rituximab: Continued Need for Evidence-Based Standardized Recommendations and Effective Implementation into Clinical Practice. *Blood* (ASH Annual Meeting Abstracts) 2012 120:97.
20. **AM Evens,** et al. The Histone Deacetylase Inhibitor (HDACi) Abexinostat): Significant Activity in Relapsed/Refractory Follicular Lymphoma (FL). Abstract 30. 12th International Conference on Malignant Lymphoma (12-ICML); Lugano, Switzerland, June 19-22, 2013.
21. R Dashnamoorthy and **AM Evens.** The Novel 2nd Generation Proteasome Inhibitor MLN9708 Induces Redox and MAPK-Dependent Cell Death in T-Cell Lymphoma (TCL) and Hodgkin Lymphoma (HL) Cell Lines and Human Lymphoma Xenograft Models. Abstract 117. 12th International Conference on Malignant Lymphoma (12-ICML); Lugano, Switzerland, June 19-22, 2013.
22. Press OW, LeBlanc M, Rimsza LM, Schoder H, Friedberg JW, Li H, Bartlett H, LaCasce A, Sweetenham J, **Evens AM,** et al. A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging: U.S. Intergroup S0816. Abstract 124. 12th International Conference on Malignant Lymphoma (12-ICML); Lugano, Switzerland, June 19-22, 2013.
23. Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Based on Interim FDG-PET Imaging: Early Results of US Intergroup S0816. Press O, Li H, Schöder H, LeBlanc M, Rimsza L, Friedberg JW, Bartlett N, LaCasce A, Sweetenham J, **Evens AM,** Straus D, Knopp M, Noy A, Hsi E, Cook J, Mittra E, Lechowicz MJ, Gascoyne RD, Miller TP, Kahl B, Cheson BD, Fisher RI. 9th International Symposium on Hodgkin’s Lymphoma. Cologne, Germany, October 2013.
24. **AM Evens** et al. Sequential Brentuximab Vedotin (BV) With Adriamycin, Vinblastine, and Dacarbazine (AVD) for Older Patients with Untreated Hodgkin Lymphoma: Preliminary Toxicity Findings from a Phase II Window Study. 9th International Symposium on Hodgkin’s Lymphoma. Cologne, Germany, October 2013.
25. Ghandi M, Petrich AM, Cassaday RD, Press OW, Shah K, Whyman J, Lansigan F, Zelenetz AD, Shah N, Fenske TS, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Karmali R, Melinamani S, Adeimy C, Smith SE, Vose JM, Dalal N, Nabhan C, Peace D, Jovanvoic B, Sohani AR, **Evens AM,** Castillo JJ, Abramson JS. Impact Of Induction Regimen and Consolidative Stem Cell Transplantation In Patients With Double Hit Lymphoma (DHL): A Large Multicenter Retrospective Analysis. *Blood* (ASH Annual Meeting Abstracts) 2013; 122:640a.
26. Scotland P, Gaulard P, Love CL, Fataccioli V, Travert M, De Leval L, Weisenburger DD, Czader M, Parihar M, Nair R, Sengar M, Beaven AW, Crow JH, Miles RR, Gordon LI, Chadburn A, **Evens AM,** Gill J, Fedoriw YD, Richards KL, Srivastava G, Choi WL, Flowers CR, Bernal-Mizrachi L, Mann KP, Naresh K, Hsi ED, Horna P, Tao J, Sun Z, Long, Zhang J, Dave S. Whole Genome and Exome Sequencing Defines The Genetic Landscape Of Hepatosplenic T-Cell Lymphoma. *Blood* (ASH Annual Meeting Abstracts) 2013; 122:842a.
27. **AM Evens** et al. Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era. *Blood* (ASH Annual Meeting Abstracts) 2013; 122:847a.
28. Rosenberg AS, Klein AK, Ruthazer R, **Evens AM.** Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder (HL-PTLD) after Solid Organ Transplant (SOT): A Comprehensive and Comparative Analysis of Disease Characteristics, Prognosis, and Survival. [Blood (ASH) 2014; 124 (21)](http://www.bloodjournal.org/content/124/21):502a.
29. **AM Evens** et al **Lipid Addiction of DLBCL:  Involvement of PI3K Signaling and Potential Therapeutic Strategies Via Fatty Acid Synthase Small Molecule Inhibitors. International Conference on Malignant Lymphoma (ICML)**: **2015, Lugano, Switzerland.**
30. **AM Evens** et al **Gray Zone Lymphoma (GZL): Characteristics, Outcomes and Prognostication Among A Large Multicenter Cohort. International Conference on Malignant Lymphoma (ICML)**: **2015**, **Lugano, Switzerland.**
31. **AM Evens** et al **Sequential Brentuximab Vedotin and AVD for Older Hodgkin Lymphoma Patients: Initial Results from a Phase 2 Multicenter Study. International Conference on Malignant Lymphoma (ICML)**: **2015**, **Lugano, Switzerland.**
32. A Mato et al and **AM Evens.** Favorable Outcomes in CLL Patients with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. Blood (ASH) 2015; 126 (23):719a.
33. **AM Evens** et al.Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408). J Clin Oncol 34, 2016 (ASCO); 7507a.
34. Henderson T and **AM Evens.** Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) Comparative Analysis; 10th International Symposium on Hodgkin Lymphoma (ISHL10), October 25, 2016; Cologne, Germany.
35. **AM Evens, et al.** Gray Zone Lymphoma (GZL) with Features Intermediate between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): A Pathologic Consensus Study with Patient Outcomes and Prognostication across 15 North American Centers Blood (ASH) 2017; 130 (24):375a.
36. **AM Evens, et al.** Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study; Blood (ASH) 2017; 130 (24):733a.
37. **AM Evens, et al.** A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD®Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group; Blood (ASH) 2017; 130 (24):482a.
38. S Purvey and **AM** **Evens.**CD19-Chimeric Antigen Receptor (CAR) Engineered Natural Killer (NK) Cell Therapy:  Novel “Off the Shelf” Immunotherapy in CD20 Resistant B-Cell Non-Hodgkin Lymphoma (NHL) Cell Lines, Primary NHL Cells, and a Human Lymphoma Xenograft Model; Blood (ASH) 2017; 130 (24):110. Blood (ASH) 2017; 130 (24):2779a.
39. Parsons SK, Kelly MJ, Cohen JT, Castellino SM, Henderson TO, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, **Evens AM.** Early-stage Hodgkin Lymphoma (HL) in the modern era: harnessing simulation modeling to delineate long-term patient outcomes. 11th International Symposium on Hodgkin Lymphoma (ISHL11), October 2018; Cologne, Germany.
40. Stephens DM and Friedberg JW. Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. Blood (ASH) 2018, 132:929.
41. Thanarajasingam G, et al. Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408; J Clin Oncol (ASCO) 37, 2019 (suppl; abstr 6511).
42. Li X, Kositsky R, Reddy A et al.Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma. Blood (ASH) 2019, 133:19.
43. Allen P, Savas H, **Evens AM.** et al. Brief Pembrolizumab (PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD. Blood (ASH) 2019, 133:235.
44. Pearse W and **Evens AM**. A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas. Blood (ASH) 2019, 133:391.
45. **Evens A,** Danilov A, Jagadeesh D, et al. The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). Blood (ASH) 2019, 133:397.
46. Zayac A, **Evens A,** Stadnik A, et al. Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. Blood (ASH) 2019, 133:402.
47. **Evens AM.** Plenary Education Session. Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine. Blood (ASH) December 2019.
48. Alderuccio JP and **Evens AM.** Characteristics and Outcomes of HIV-Related Burkitt Lymphoma (HIV-BL) in the Post-Rituximab Era Across 30 US Cancer Centers. EHA Library (European Hematology Association). 06/12/20; 295059; abstract S239.
49. David KA and **Evens AM.** Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. December 2020 ASH Annual Meeting. Abstract 476.
50. Olszewski AJ and **Evens AM,** The Burkitt Lymphoma International Prognostic Index (BL-IPI). December 2020 ASH Annual Meeting. Abstract 705.
51. Alderuccio JP, Olszewski AJ, **Evens AM**, et al.Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. December 2020 ASH Annual Meeting. Abstract 706.

***Professional presentations (last 5 years only):***

1. CLL in 2015; Steeplechase Cancer Center Grand Rounds, Robert Woods Johnson University; Somerville, NJ, February 6th, 2015.
2. Aggressive B-Cell Non-Hodgkin Lymphoma; for Lymphoma Research Foundation (LRF) 2015 Arizona Lymphoma Workshop; Scottsdale, AZ; February 28th, 2015.
3. Elderly Hodgkin Lymphoma: The Dark Side? 1st Postgraduate Lymphoma Conference; Rome, Italy; March 26-27th, 2015.
4. Prognosis and Treatment of Hodgkin Lymphoma: Current Status and Future Directions; 15th Annual William Burnham Memorial Speaker and Grand Rounds; Rochester, NY; April 15th, 2015.
5. Cutaneous T-cell Lymphoma: A Disease State Overview, Summit, New Jersey; August 11th, 2015.
6. Lymphoma: Fourth Annual "Year in Review" (YIR) Neil Love regional, New York, New York; October 3rd, 2015.
7. Lymphoma Research Foundation 20th Annual North American Educational Forum on Lymphoma.  CNS Lymphoma-Novel Therapies  & Clinical Trials in Lymphoma Treatment; October 4th, 2015.
8. Hematologic Malignancies - Tumor Concepts in Personalized Medicine; National Cancer Institutes/NantWorks Scientific Meeting; Bethesda, MD; October 21, 2015.
9. New Developments in the Management of Hodgkin Lymphoma. Virginia Oncology Assoc. for the Duke Cancer Network; 16th Educational Conference; Virginia Beach, VA; November 14th, 2015.
10. New Therapeutic Options for CLL and Integration into Patient Care. Mercy Medical Center Grand Rounds; Springfield, MA; November 18th, 2015.
11. ASH Friday Satellite Symposium: Capitalizing on Recent Advances in Hodgkin Lymphoma. December 4th, 2015.
12. Non-Hodgkin Lymphoma: Path Forward in Personalized Therapy. National Immunotherapy Summit; Santa Cruz, CA; January 16th, 2016.
13. What’s new in the initial management of Hodgkin Lymphoma? Great Debates and Updates in Hematologic Malignances, to be held April 1, 2016 - April 2, 2016 at the New York Marriott Downtown, in New York, New York.
14. Low-grade Non-Hodgkin’s Lymphoma: follicular and marginal zone lymphoma. Mexican Society of Hematology (AMEH) and ASH; Merida, Mexico; Apr 29, 2016.
15. 13th International Ultmann Chicago Lymphoma Symposium; May 7th, 2016; Chicago.
16. Understanding Lymphoma (Plenary Session); Lymphoma Research Foundation (LRF) New England Lymphoma Annual Workshop, May 21st, 2016; Needham, MA.
17. Aggressive B-Cell Non-Hodgkin Lymphoma  (Disease Specific Breakout Sessions); Lymphoma Research Foundation (LRF) New England Lymphoma Annual Workshop, May 21st, 2016; Needham, MA.
18. ASCO Educational Session: PET-Directed Therapy for Early-Stage Hodgkin Lymphoma; American Society of Clinical Oncology (ASCO) Annual Meeting, June 2016.
19. Lymphoma Overview; Best of ASCO (Sponsor: ASCO); Washington DC; July 16th, 2016.
20. PET Directed Therapy for Early Stage Hodgkin Lymphoma. Pan Pacific Lymphoma Conference (Sponsor: University of Nebraska); July 19th, 2016; Kauai, Hawaii.
21. Non-LP CD20+ Hodgkin Lymphoma (ie, Gray Zone Lymphoma). Pan Pacific Lymphoma Conference (Sponsor: University of Nebraska); July 20th, 2016; Kauai, Hawaii.
22. Optimizing (NK-Cell) Immunotherapy for the Treatment of Lymphoma The Immuno-Oncology Summit (Cambridge Healthtech Institute); August 31, 2016; Boston, MA.
23. Lymphoma During Pregnancy; Mother Infant Research Institute (MIRI) Scientific Seminar; September 16th, 2016; Tufts MC, Boston, MA.
24. Double Hit Lymphoma: How to Approach in the Contemporary Era. The New England Lymphoma Rounds (Sponsor: LRF); September 20, 2016; Boston, MA.
25. Treatment of Limited Stage Hodgkin Lymphoma: Is RT Necessary? The Inaugural Lymphoma Rounds (Sponsor: Imedex, LLC and LRF); October 16, 2016; NY, NY.
26. Hodgkin Lymphoma in Elderly Patients: The US Experience. Scientific Workshop at the 10th International Symposium on Hodgkin Lymphoma (ISHL10), October 22, 2016; Cologne, Germany.
27. Grey Zone Lymphoma. Scientific Workshop at the 10th International Symposium on Hodgkin Lymphoma (ISHL10), October 22, 2016; Cologne, Germany.
28. Hodgkin Lymphoma: Disease-specific Breakout Session I for the Annual LRF Lymphoma Educational Forum; October 29th, 2016; Chicago, IL.
29. Immunotherapy for the Treatment of Lymphoma: Shooting for the Moon. Massachusetts Society of Clinical Oncologists (MSCO) Annual Meeting: Key Note Speaker; November 3rd, 2016; Boston, MA.
30. Clinical Updates in T-cell Lymphoma and Hodgkin Lymphoma. New England Cancer Specialists (NECS); February 7th, 2017; Scarborough, Maine.
31. Cancer Center Grand Rounds: Clinical Updates in T-cell Lymphoma and Hodgkin Lymphoma. Montefiore Medical Center; January 20th, 2017; Bronx, NY.
32. Grand Rounds: Canine T Cell Lymphoma: Unleashing Canine Omics. Cornell University’s College of Veterinary Medicine; Department of Biomedical Sciences and Center for Reproductive Genomics. Jan 31st 2017; Ithaca, NY.
33. Cancer Center Grand Rounds: Clinical Updates in T-cell Lymphoma and Hodgkin Lymphoma. Lenox Hill Hospital; March 21st, 2017; New York, NY.
34. Cancer Center Grand Rounds: Clinical Updates in T-cell Lymphoma and Hodgkin Lymphoma. Lowell General Hospital; March 29th, 2017; Lowell, MA.
35. Cancer Center Grand Rounds: Clinical Updates in T-cell Lymphoma and Hodgkin Lymphoma. University of Nebraska; May 16th, 2017; Omaha, NE.
36. Lymphoma and Chronic Lymphocytic Leukemia. American Society of Clinical Oncology (ASCO) Annual Meeting. Poster Discussion Session; June 5th, 2017; Chicago, IL.
37. Cancer Center Grand Rounds. Yale Cancer Center. Hodgkin Lymphoma:  Poised for the Application of Precision Medicine. September, 11th, 2017. New Haven, CT.
38. Lymphoma Overview: Opening Plenary Session; North American Ed Forum, Lymphoma Research Foundation; October 21st, 2017. Brooklyn, NY.
39. Understanding Clinical Trials Seminar. North American Ed Forum, Lymphoma Research Foundation; October 21st, 2017. Brooklyn, NY.
40. Demystifying the Clinical Trial Experience: Bridging the Investigator and Patient Perspective, Plenary Session; North American Ed Forum, Lymphoma Research Foundation; October 22nd, 2017. Brooklyn, NY.
41. How to manage lymphocyte predominant Hodgkin lymphoma. *Lymphoma & Myeloma 2017: An International Congress on Hematologic Malignancies*. October 28th, 2017. New York, NY.
42. Mentored Rutgers CINJ Hematology/Oncology fellow, Dr. Pallvi Popli, and moderated a session/presentation on “Breast Implant Associated Lymphoma” for the Lymphoma Research Foundation (LRF) ‘Lymphoma Rounds’; January 28th, 2018; New York, New York.
43. Formulating a Career Development Plan/Research Grants Beyond CDAs; Lymphoma Research Foundation, Annual Clinical Research Mentoring Program, March 9th, 2018.
44. How to Publish for Lymphoma Related Research; Lymphoma Research Foundation, Annual Clinical Research Mentoring Program, March 10th, 2018.
45. Medical Grand Rounds: Modern Treatment of Hodgkin Lymphoma: Prognostication, Curability & Survivorship; April 11th, 2018; St. Barnabas Medical Center, Livingston, NJ.
46. Oral Chemotherapy Adherence & Management of Toxicities (For Nursing Session); 15th International Ultmann Chicago Lymphoma Symposium on the Diagnosis and Management of Lymphoma, The University of Chicago and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University. May 4th, 2018; Chicago, IL
47. Small Molecules on the Horizon in Lymphoma (*non-immunotherapy!*); 15th International Ultmann Chicago Lymphoma Symposium, The University of Chicago and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University; May 4th, 2018; Chicago, Illinois
48. Updates in Lymphoma (Neil Love Research To Practice); ONS annual meeting; May 16th, 2018; Washington, DC
49. Aggressive B-cell Lymphomas. Emerging Therapies for Lymphomas; Co-Chair: Emerging Therapies for Lymphomas; Leukemia and Lymphoma Society; Newark, Delaware; May 17th, 2018.
50. Lymphoma Research Foundation (LRF) Staff Learning Lab: Post-ASCO Overview; New York, New York; June 19th, 2018.
51. Support Systems and Infrastructure for Young Cancer Investigators. Biden Cancer Community Summit; Lymphoma Research Foundation; September 21st, 2018; New York, New York
52. Lymphoma Clinical Update: Hodgkin Lymphoma and T-cell lymphoma; Disease Education Hunterdon Regional Cancer Center; September 27th, 2018; Flemington, NJ
53. T-cell lymphoma: ATLL. Philadelphia Lymphoma Rounds; Lymphoma Research Foundation; October 3rd, 2018; Philadelphia, Pennsylvania.
54. NHL-High Grade and Hodgkin Lymphoma; LLS Blood Cancer Conference; October 6th, 2018; New York, New York
55. Updates in Lymphoma; Harnessing New Targeted Therapies in Hematologic Malignancies; LLS Professional Education Program; October 11th, 2018, Spring Lake, New Jersey
56. Precision Oncology in Lymphoma. 2018 North American Educational Forum on Lymphoma; October 13th, 2018; Manhattan Beach, CA
57. Young Investigator Research; 2018 North American Educational Forum on Lymphoma; October 14th, 2018; Manhattan Beach, CA
58. Lymphoma Clinical Update: Hodgkin Lymphoma and T-cell lymphoma; Mercer Bucks Hematology Oncology, Capital Health System; October 16th, 2018; Pennington, NJ
59. T-cell lymphoma: ATLL. New York Lymphoma Rounds; Lymphoma Research Foundation; October 18th, 2018; New York, New York
60. What is the best upfront approach for the treatment of advanced stage Hodgkin lymphoma? Debate at: Lymphoma & Myeloma 2018: An International Congress on Hematologic Malignancies; October 20th, 2018; New York, New York
61. Brentuximab/Chemotherapy Combinations in Elderly HL. Challenges in Older Lymphoma Patients Workshop. 11th International Symposium on Hodgkin Lymphoma (ISHL11); October 27th, 2018; Cologne, Germany
62. Biosimilars in Primary Care: Strategies for Improving Patient Management, PriMED CME symposium; November 8th, 2018; New York, New York
63. Treatment of Hodgkin Lymphoma in 2018 and Beyond; OncLive Regional Seminar Series – Hodgkin Lymphoma. November 13th, 2018; New Brunswick, NJ
64. Moving Toward a Cure for More Patients With Hodgkin Lymphoma: Expert Guidance and Practical Case Discussions. ASH Friday Satellite Symposium; November 30th, 2018; San Diego, CA
65. Hodgkin Lymphoma News From ASH 2018: Updates From Leading Experts; for Patient Power; December 5th, 2018; San Diego, CA (<https://www.patientpower.info/video/hodgkin-lymphoma-news-from-ash-updates-from-leading-experts>)
66. Update on Lymphoma from the 2018 ASH Meeting; for Cancer Care and Lymphoma Research Foundation (Tele-Conference and Webcast); NY, New York; January 15th, 2019; <https://www.cancercare.org/connect_workshops/703-lymphoma_american_society_hematology_ash_2019-01-15>
67. Lymphoma Clinical Update: Hodgkin Lymphoma and T-cell Lymphoma; Yale University and the Smilow Cancer Center; January 17th, 2019; New Haven, CT
68. Progressive Transformation of Germinal Centers. New York Lymphoma Rounds; Lymphoma Research Foundation; January 24th, 2019; New York, New York
69. New Systemic Therapies in Hodgkin Lymphoma. Modern Radiotherapy for Hematologic Malignancies (ASTRO Annual Education Symposium); February 16th, 2019; University of California, San Diego, La Jolla, CA.
70. Medical Oncology Review of Diffuse Large B-Cell Lymphoma. Modern Radiotherapy for Hematologic Malignancies (ASTRO Annual Education Symposium); February 17th, 2019; University of California, San Diego, La Jolla, CA.
71. Decision Making in Hodgkin Lymphoma; Medical Grand Rounds, Memorial Sloan Kettering Cancer Center; February 12th, 2019; New York, NY
72. Hodgkin Lymphoma (ASH Updates); ASH in Asia Pacific annual meeting; February 23rd, 2019; Bangkok, Thailand
73. Selection and Sequencing of Systemic Therapy in the Management of Follicular Lymphoma; February 28th, 2019; Lankenau Medical Center; Wynnewood, PA
74. Have We Made Progress in Managing T-Cell Lymphoma? *23rd Annual*International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma. March 2nd, 2019; Miami, FL
75. How to Become Involved in Co-Operative Groups, CTEP, and other collaborative research efforts; and Formulating a Career Development Plan/Research Grants Beyond CDAs; Lymphoma Research Foundation Clinical Research Mentoring Program (LCRMP) via Lymphoma Research Foundation; March 6th to 9th, 2019; Scottsdale, AZ
76. Grand Rounds: Lymphoma Clinical Update; St Michael's Cancer Center; March 21st, 2019; Newark, New Jersey
77. Lymphoma Clinical Update at Great Debates in Hematologic Malignancies; April 6th; 2019; New York, New York
78. Clinical Research Design Course - How do I design a clinical trial; Rutgers CINJ Clinical Research Design Course; April 10th, 2019; New Brunswick, New Jersey
79. Grand Rounds: Lymphoma Clinical Update; Valley-Mount Sinai Comprehensive Cancer Care; May 9th 2019; Paramus, New Jersey
80. Hodgkin Lymphoma in the Elderly. The [4th Annual Memorial Sloan Kettering (MSK) Symposium on Lymphoma](https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmskcc.cloud-cme.com%2Fdefault.aspx%3FP%3D5%26EID%3D9096&data=02%7C01%7Cae378%40cinj.rutgers.edu%7C000550eb5dd04c86166208d6555c9363%7Cb92d2b234d35447093ff69aca6632ffe%7C1%7C1%7C636790254454193387&sdata=6ZtphTIg0E1iJ6NpBJ0Ut5%2BvMGC1UGgB8hnpSRW%2BEQk%3D&reserved=0). May 11th, 2019; New York, New York
81. The Role of Clinical Trials: How Research Contributes to Your Treatment Options; Cancer*Care* Teleconference – Progress in the Treatment of Non-Hodgkin Lymphoma (NHL); June 13th, 2019, New Brunswick, New Jersey
82. Lymphoma Clinical Update; Regional Hematology Oncology Associates; August 28th, 2019, Langhorne, Pennsylvania
83. How I Treat Hodgkin Lymphoma. ASH Annual Meeting on Hematologic Malignancies (MHM), September 6th and 7th, 2019, Chicago, Illinois
84. How I Treat Early Stage Hodgkin Lymphoma. Society of Hematologic Oncology's Seventh Annual Meeting (SOHO 2019); MD Anderson Cancer Center; September 13th, 2019, Houston, Texas;
85. Grand Rounds in B-Cell Lymphoma; Allegheny General Hospital; October 7th, 2019, Pittsburgh, Pennsylvania
86. Lymphoma Updates, Year in Review CME symposia; Research To Practice; October 12th, 2019, Santa Monica, California
87. Hodgkin Lymphoma (disease breakout); North American Educational Forum on Lymphoma; Lymphoma Research Foundation (LRF); October 19th, 2019, Chicago, Illinois
88. [How Best to Approach Hodgkin Lymphoma in Older Patients](https://www.conferenceharvester.com/harvester2/reports/details.asp?PresentationID=981789); Lymphoma & Myeloma Congress; Weill Cornell Medicine; October 25th, 2019, New York, New York
89. CD19 Natural Killer Based Therapeutic Paradigms in Non-Hodgkin Lymphoma; Rutgers Institute for Quantitative Biomedicine (IQB) and Rutgers Cancer Institute of New Jersey (CINJ) crash course “Engineering Immune Cells to Fight Cancer”; October 29th, 2019, New Brunswick, New Jersey
90. Hodgkin Lymphoma: Who Should Receive A+AVD Therapy? *37th Annual* CFS: Innovative Cancer Therapy for Tomorrow; November 6th, 2019, New York, New York
91. Grand Rounds in B-Cell Lymphoma; Mercy Medical Center; November 8th, 2019; Springfield, Massachusetts
92. Grand Rounds in B-Cell Lymphoma; SUNY Downstate Medical Center; November 8th, 2019; Brooklyn, New York
93. Annual Meeting Education Sessions. Topic: Hodgkin Lymphoma: Celebrating 200 Years Since Thomas Hodgkin Entered Medicine. Blood (ASH) December 2019.
94. Mantle Cell Lymphoma Roundtable for MDedge Hematology & Oncology (via Medscape), NY, NY, January 27th, 2020
95. Rutgers CINJ led event ASH Review 2019 (via Leukemia & Lymphoma Society); Spring Lake, New Jersey, February 13th, 2020
96. Updates in Hodgkin Lymphoma; Challenging Cases® in Hematology event; NY, NY; February 22nd, 2020
97. Current and Future Treatment of Hodgkin Lymphoma; Opinions in Hematologic Malignancies: Winter National Summit (Sponsor: Curios Science); Banff, Canada; February 28th, 2020
98. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL); Teleconference Podcast via CancerCare (virtual); April 16th, 2020
99. Community Opinions in CD30-Expressing Lymphomas Workshop; Curios Science; Boston, MA (virtual) April 16th, 2020.
100. Northeast Virtual Lymphoma Workshop WebCast (patient education) via LRF (virtual); April 25th, 2020.
101. Preparing for the Post-COVID Surge:  A Discussion for Cancer Centers”.  ECG-hosted event (virtual); May 7th, 2020.
102. B-Cell Webinar Grand Rounds via Dr Neil Love and Research to Practice; Lankenau Medical Center, Philadelphia, PA (virtual); May 14th, 2020
103. B-Cell Webinar Grand Rounds via Dr Neil Love and Research to Practice; Blue Ridge Cancer Care Carilion Cancer Center (virtual); May 21st, 2020
104. Opinions in CD30-Expressing Lymphomas: An Interactive Local Virtual Workshop, Curios Science; Denver, CO; June 4th, 2020.
105. BTK Inhibitors in B-Cell Malignancies: An OncLive Scientific Interchange and Workshop, Curios Science; OncLive; New York, New York (virtual); June 12th, 2020
106. Opinions in CD30-Expressing Lymphomas: An Interactive Local Virtual Workshop, Curios Science; New York, New York (virtual); June 30th, 2020
107. Opinions in CD30-Expressing Lymphomas: An Interactive Local Virtual Workshop, Curios Science; Miami, Florida (virtual); July 8th, 2020
108. CLL Connection: Dinner with the Docs. Patient Power (<https://patientpower.info/nj>); Somerset, NJ (virtual); July 13th, 2020
109. Opinions in CD30-Expressing Lymphomas: An Interactive Local Virtual Workshop, Curios Science; Detroit, MI (virtual), July 14th, 2020
110. Updates in Elderly Hodgkin Lymphoma; for the Israeli Lymphoma; Tel Aviv, Israel (virtual); July 20th, 2020
111. Opinions in CD30-Expressing Lymphomas: An Interactive Local Virtual Workshop, Curios Science; Milwaukee, WI (virtual), August 6th, 2020
112. Opinions in CD30-Expressing Lymphomas: An Interactive Local Virtual Workshop, Curios Science; Minneapolis; August 20th, 2020.
113. Opinions in CD30-Expressing Lymphomas: An Interactive Local Virtual Workshop, Curios Science; Columbus, OH; September 2nd, 2020.
114. Opinions in CD30-Expressing Lymphomas: An Interactive Local Virtual Workshop, Curios Science; Hamilton, New Jersey; September 9th, 2020.
115. Opinions in CD30-Expressing Lymphomas: An Interactive Local Virtual Workshop, Curios Science; Atlanta, GA; October 6th, 2020.
116. Opinions in CD30-Expressing Lymphomas: An Interactive Local Virtual Workshop, Curios Science; Boston, MA; October 8th, 2020.
117. Opinions in CD30-Expressing Lymphomas: An Interactive Local Virtual Workshop, Curios Science; St. Louis, MO; October 15th, 2020.
118. Opinions in CD30-Expressing Lymphomas: An Interactive Local Virtual Workshop, Curios Science; Chicago, IL; November 5th, 2020.
119. Opinions in Follicular Lymphoma: An Interactive Local Virtual Workshop Series; Boston, MA; October 28th, 2020.
120. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Westchester, NY; January 21st, 2021.
121. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Madison, WI; January 26th, 2021.
122. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Chicago, IL; January 28th, 2021.
123. OncLive Peer Exchange on Follicular lymphoma panel; January 29th, 2021.
124. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Chicago, IL; February, 9th, 2021.
125. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Princeton, NJ; February 11th, 2021.
126. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; New York, New York; February 16th, 2021.
127. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Chicago, February 21st, 2021.
128. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Portland, ME; February 23rd, 2021.
129. New Targeted Therapies in Hematologic Malignancies (post-ASH update); LLS Professional Education Program; Spring Lake, New Jersey; February 25th, 2021
130. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Charleston, WV, March 2nd, 2021.
131. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Harrisburg, PA; March 4th, 2021.
132. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Philadelphia, PA; March 9th, 2021.
133. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Albany, NY; March 11th, 2021.
134. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Columbus, OH; March 16th, 2021.
135. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Newark, NJ; March 18th, 2021.
136. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Scranton, PA; March 23rd, 2021.
137. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Hartford, CT; March 25th, 2021.
138. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Southern, NJ; March 30th, 2021.
139. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Philadelphia, PA; April 6th, 2021.
140. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Long Island, NY; April 8th, 2021.
141. Levering Multisource Data to Enhance Decision Making in Hodgkin lymphoma; Northeast Adolescent & Young Adult (AYA) Annual Cancer Conference; Boston, MA; April 9th, 2021.
142. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Boston, MA; April 13th, 2021.
143. COVID-19 Vaccine: What the Lymphoma Community Needs to Know Webinar (with Dr. Brian Strom); Lymphoma Research Foundation (LRF); April 13th, 2021.
144. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Washington, DC; April 15th, 2021.
145. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Providence, RI; April 20th, 2021.
146. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Cincinnati, OH; April 22nd, 2021.
147. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; Baltimore, MD; April 27th, 2021.
148. Opinions in Hodgkin Lymphoma: An Interactive Local Virtual Workshop Series; New York,New York; April 29th, 2021.
149. Progress in the Treatment of Non-Hodgkin Lymphoma (NHL); Teleconference Podcast via CancerCare (virtual); May 20th, 2021

***Media outreach,*** print and electronic(past 15 months only):

Targeted Oncology, COVID and Cancer, March 2020: <https://www.targetedonc.com/view/expert-addresses-oncology-practice-concerns-amidst-covid19-outbreak-in-the-united-states>

CINJ Telemedicine, 2020: <https://www.cinj.org/patient-care/from-a-distance>

Cancer Care Webinar April 2020: <https://www.cancercare.org/connect_workshops/800-progress_in_the_treatment_of_nhl_2020-04-16>

Rutgers, Telemedicine, April 2020: <https://www.rutgers.edu/news/coronavirus-speeds-use-telemedicine-rutgers>

CINJ, May 2020: <https://www.cinj.org/building-international-consortium-enhance-decision-making-hodgkin-lymphoma>

Patient Power, Dinner with the Docs (CLL), July 2020: [https://patch.com/new jersey/newbrunswick/calendar/event/20200713/851057/patient-power-to-host-dinner-with-the-docs-virtual dinner-event](https://patch.com/new%20jersey/newbrunswick/calendar/event/20200713/851057/patient-power-to-host-dinner-with-the-docs-virtual%20dinner-event)

CINJ COVID Cancer Care, 2020: <https://www.cinj.org/patient-care/cancer-care-covid-19-world>

CINJ COVID Cancer Care, 2020: <https://www.rutgers.edu/news/impact-coronavirus-pandemic-cancer-care>

Youtube; Docs and COVID, Doctor Mike: <https://www.youtube.com/watch?v=WhHfjsOl8Tc&feature=youtu.be>

ASCO Post, July 2020: <https://ascopost.com/issues/july-10-2020/international-consortium-aims-to-enhance-decision-making-in-hodgkin-lymphoma/#.XxZOu6GK9kM.twitter>

Oncology Tube, ASH 2020: <https://www.oncologytube.com/video/39713/andrew-m.-evens-do-msc-draevens-rutgerscancer-ash20-lymphoma-cancer-research-the-burkitt-lymphoma-international-prognostic-index?channelName=ASHReport_5f6a1d25488df>

Oncology Tube, ASH 2020: <https://www.oncologytube.com/video/39714/andrew-m.-evens-do-msc-draevens-rutgerscancer-ash20-lymphoma-cancer-research-real-world-outcomes-and-prognostication-of-older-pcnsl-in-the-contemporary-era>

Foundation Medicine, Youtube, ASH 2020: <https://www.youtube.com/watch?v=rorh_7Y8Y5c&feature=youtu.be>

Welcome to the first @RutgersCancer Twitter Chat, September 2020: <https://cinj.org/twitter-chat-recap-addressing-leukemialymphoma-covid-19-world>

NJ 101.5, COVID and Cancer, November, 2020: <https://nj1015.com/cancer-care-continues-even-amid-covid-19-precautions/>

New Jersey and COVID, November 2020: <https://patch.com/new-jersey/newbrunswick/impact-coronavirus-pandemic-cancer-care>

Targeted Oncology, December 2020: <https://www.targetedonc.com/view/2020-ash-recap-hematologists-review-most-impactful-data-across-hematologic-malignancies>

Oncology Learning Network, December 2020: <https://www.oncnet.com/videos/recent-updates-treatment-fl>

USA Today, December 2020: <https://www.usatoday.com/story/news/health/2020/12/06/covid-update-southern-california-lockdown-cdc-issues-dire-warning/3840929001/>

HoLISTIC ASH 2020: <https://www.youtube.com/watch?v=xbZ0w72nx8Y>

OncLive, Follicular Lymphoma peer panel, February 2021: <https://twitter.com/OncLive/status/1364741923643281413?s=20> and <https://www.onclive.com/view/clinical-updates-on-relapsed-refractory-follicular-lymphoma?seriesVid=1>